MIRA INFORM REPORT
|
Report Date : |
29.03.2012 |
IDENTIFICATION DETAILS
|
Name : |
CARL ZEISS MEDITEC AG |
|
|
|
|
Registered Office : |
Goeschwitzer Strasse 51-52, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
30.09.2011 |
|
|
|
|
Year of Establishment : |
1977 |
|
|
|
|
Com. Reg. No.: |
205623 |
|
|
|
|
Legal Form : |
Public Subsidiary Company |
|
|
|
|
Line of Business : |
Subject is a Germany-based medical technology solutions supplier, specializing in Ophthalmology and Neuro/Ear Nose Throat surgery |
|
|
|
|
No. of Employees
: |
2366 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Germany |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52
Jena, 07745
Germany
Tel: 49-36-412200
Fax: 49-36-41220112
synthesis
Employees: 2,366
Company Type: Public Subsidiary
Corporate Family: 107
Companies
Ultimate Parent: Carl-Zeiss-Stiftung
Traded: XETRA: AFX
Incorporation Date: 1977
Auditor: KPMG AG
Financials in: USD
(Millions)
Fiscal Year End:
30-Sep-2011
Reporting Currency: Euro
Annual Sales: 1,057.2 1
Net Income: 93.2
Total Assets: 1,163.9 2
Market Value: 1,698.2
(06-Jan-2012)
Business Description
Carl Zeiss Meditec AG is a Germany-based medical technology solutions
supplier, specializing in Ophthalmology and Neuro/Ear Nose Throat surgery. Its
diagnostic and therapeutic solutions are used for treating four main ophthalmic
conditions: vision defects, cataracts, glaucoma and retinal disorders. The
Company's solutions include optical biometry equipment; optical coherence
tomography equipment; lens analyzers; fundus imaging cameras; standard and
refractive ophthalmic lasers and slit lamps. In the field of Neurosurgery, it
offers visualization solutions and surgical microscopes, used in clinical
treatment of accidents, nerve reconstruction and pediatric neurosurgery. It is
also involved in the development of visualization solutions in the area of
intraoperative radiation therapy. The Company has subsidiaries in Germany,
France, Spain, the United States, Japan, Mauritius and the United Kingdom, as
well as distribution companies and agencies globally. For the fiscal year ended
30 September 2011, Carl ZeissMeditec AG's net sales increased 12% to EUR758.8M.
Net income for the period increased 22% to EUR66.9M. Net sales reflect
increased demand for the Company's products and services in the Surgery,
Ophthalmology and Microsurgery business segments. Net income for the period
benefited from higher interest income as well as from lower other operating
expense.
Industry
Industry Medical Equipment and Supplies
ANZSIC 2006: 2412 - Medical and
Surgical Equipment Manufacturing
NACE 2002: 3310 - Manufacture
of medical and surgical equipment and orthopaedic appliances
NAICS 2002: 334510 - Electromedical
and Electrotherapeutic Apparatus Manufacturing
UK SIC 2003: 3310 - Manufacture
of medical and surgical equipment and orthopaedic appliances
US SIC 1987: 3845 -
Electromedical and Electrotherapeutic Apparatus
Key Executives
|
Name |
Title |
|
Ludwin Monz |
Chairman of the Management Board, Chief
Executive Officer |
|
Christian Muller |
Director and Chief Financial Officer |
|
Thomas Simmerer |
Chief Sales Officer, Member of the
Management Board |
|
Cornelia Grandy |
Member of the Supervisory Board |
|
Jens Brajer |
Director of Corporate Functions |
Significant Developments
|
Topic |
#* |
Most Recent
Headline |
Date |
|
Mergers & Acquisitions |
1 |
Carl Zeiss Meditec AG to Acquire
Intraocular Lens and Ophthalmic Viscoelastic Devices Business of IMEX |
21-Sep-2011 |
|
Business Deals |
1 |
Carl Zeiss Meditec AG's Carl Zeiss NTS,
LLC Secures IARPA R&D Contract For Gas Field Ion Source Technology |
7-Feb-2011 |
|
Other Pre-Announcement |
1 |
Carl Zeiss Meditec AG Reaffirms FY
2010/2011 Guidance-Conference Call |
5-May-2011 |
|
Positive Earnings Pre-Announcement |
1 |
Carl Zeiss Meditec AG Issues FY 2010/2011
Guidance Above Analysts' Estimates |
11-Feb-2011 |
|
Dividends |
1 |
Carl Zeiss Meditec AG to Distribute FY
2010 Dividend |
1-Mar-2011 |
* number of significant developments within the last 12 months
News
|
itle |
Date |
|
Carl Zeiss
Meditec Announces New Dry AMD and Glaucoma Clinical Applications for Cirrus
HD-OCT |
20-Jan-2012 |
|
Optovue and
Carl Zeiss Meditec Have Reached Settlement in Their Current Patent
Infringement Disputes |
10-Jan-2012 |
|
Directors'
dealings:Carl Zeiss Meditec AG:Director's Dealings announcement according to
§15a WpHG (the German Securities Trading Act) |
10-Jan-2012 |
|
Financial
Statements 2010/2011 Carl Zeiss Meditec AG Earnings Conference Call - Final |
22-Dec-2011 |
|
Carl Zeiss
Meditec annual net income up |
16-Dec-2011 |
Financial Summary
As of 30-Sep-2011
Key Ratios Company Industry
Current Ratio (MRQ) 3.72 2.84
Quick Ratio (MRQ) 2.94 1.96
Debt to Equity (MRQ) 0.05 0.37
Sales 5 Year Growth 14.21 13.75
Net Profit Margin (TTM) % 9.52 10.96
Return on Assets (TTM) % 8.46 7.42
Return on Equity (TTM) % 11.42 13.52
Stock Snapshot
|
Registered No.(DEU): 205623
1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.717768
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7453231
Corporate Overview
Location
Goeschwitzer Strasse 51-52
Jena, 07745
Germany
Tel: 49-36-412200
Fax: 49-36-41220112
Quote Symbol - Exchange
AFX - XETRA
Sales EUR(mil): 758.8
Assets EUR(mil): 867.5
Employees: 2,366
Fiscal Year End: 30-Sep-2011
Industry: Medical
Equipment and Supplies
Incorporation Date: 1977
Company Type: Public
Subsidiary
Quoted Status: Quoted
Registered No.(DEU): 205623
Chairman of the
Management Board,
Chief Executive Officer: Ludwin
Monz
Company Web Links
· Company Contact/E-mail
· Corporate History/Profile
· Employment Opportunities
· Executives
· Financial Information
· Home Page
· Investor Relations
· News Releases
· Products/Services
Contents
· Industry Codes
· Business Description
· Financial Data
· Market Data
· Shareholders
· Subsidiaries
· Key Corporate Relationships
Industry Codes
ANZSIC 2006 Codes:
2412 - Medical and Surgical Equipment Manufacturing
NACE 2002 Codes:
3310 - Manufacture of medical and surgical equipment and
orthopaedic appliances
NAICS 2002 Codes:
334510 - Electromedical and Electrotherapeutic Apparatus
Manufacturing
US SIC 1987:
3845 - Electromedical and Electrotherapeutic Apparatus
UK SIC 2003:
3310 - Manufacture of medical and surgical equipment and
orthopaedic appliances
Business Description
Carl Zeiss Meditec
AG is a Germany-based medical technology solutions supplier, specializing in
Ophthalmology and Neuro/Ear Nose Throat surgery. Its diagnostic and therapeutic
solutions are used for treating four main ophthalmic conditions: vision
defects, cataracts, glaucoma and retinal disorders. The Company's solutions
include optical biometry equipment; optical coherence tomography equipment;
lens analyzers; fundus imaging cameras; standard and refractive ophthalmic
lasers and slit lamps. In the field of Neurosurgery, it offers visualization
solutions and surgical microscopes, used in clinical treatment of accidents,
nerve reconstruction and pediatric neurosurgery. It is also involved in the
development of visualization solutions in the area of intraoperative radiation
therapy. The Company has subsidiaries in Germany, France, Spain, the United
States, Japan, Mauritius and the United Kingdom, as well as distribution
companies and agencies globally. For the fiscal year ended 30 September 2011,
Carl ZeissMeditec AG's net sales increased 12% to EUR758.8M. Net income for the
period increased 22% to EUR66.9M. Net sales reflect increased demand for the
Company's products and services in the Surgery, Ophthalmology and Microsurgery
business segments. Net income for the period benefited from higher interest
income as well as from lower other operating expense.
More Business Descriptions
Carl Zeiss Meditec
is an integrated medical technology company. The company manufactures
ophthalmic diagnostic and therapeutic products, including examination and
surgical microscopes, diagnostic systems, laser surgery equipment, and
intraocular lenses. It operates several branch offices engaged in the production,
sales, services, and research and development; as well as authorized sales and
service locations across the regions of Americas, Europe and Asia-Pacific. Carl
Zeiss Meditec has holdings in about 14 subsidiaries located in the US, France,
Japan, Spain, the UK and Germany. The company’s research and development
(R&D) activities are focused on examining new technological concepts in
terms of their clinical relevance and effectiveness; expansion of its product
portfolio through the development of new products and product platforms based
on the available basic technologies. During fiscal year 2010, Carl Zeiss
Meditec spent about 72.35 million, which accounted for 10.69% of its total
revenue. It employed about 353 people in its R&D activities by the end of
30 September 2010. Recently, Carl Zeiss Meditec receved $22.6m contract from
the Air Force Research Laboratory, Wright Patterson Air Force Base, to develop
certain nano manufacturing and imaging applications based on its ORION gas
field ion source (GFIS) technology. The company was awarded the prestigious
2010 Spine Technology Award for its INTRABEAM system, which offers an
alternative way of treating spine metastases. Carl Zeiss Meditec launched the
FORUM Glaucoma Workplace, the VISULAS 532s VITE laser system, and also received
clearance for its new indications in VisuMax Femtosecond Laser.Carl Zeiss
Meditec classifies its geographic operations into four regions, namely,
Germany, the US, Japan and Europe. During fiscal year 2010, the company
generated about 37.2% of its total revenues from Germany, followed by the US
(33.5%), Japan (14.5%) and Europe (14.8%). The company principally operates
through three reportable business segments, namely, Ophthalmic Systems;
Surgical Ophthalmology; and Microsurgery.
Carl Zeiss Meditec
AG (Carl Zeiss Meditec) is a medical equipment company engaged in developing,
manufacturing and marketing of medical laser and diagnostic systems,
intraocular lenses and consumables for ophthalmic surgery. It is an integrated
medical technology company which operates in the fields of ophthalmology,
neuro/ENT surgery and surgical ophthalmology. The company’s research and
development activities are principally into the development of extreme
ultraviolet lithography (EUV). Carl Zeiss Meditec conducts operations through
its subsidiaries in Germany, France, Spain, North America and Japan. Its
products are marketed through 40 distribution companies and over 100 agencies
worldwide. The company is headquartered in Jena, Germany.The company reported
revenues of (Euro) EUR 676.68 million during the fiscal year ended September
2010, an increase of 5.72% over 2009. The operating profit of the company was
EUR 86.74 million during the fiscal year 2010, an increase of 14.01% over 2009.
The net profit of the company was EUR 54.89 million during the fiscal year
2010, an increase of 8.60% over 2009.
Medical technology
company: development, manufacture and marketing of medical laser and diagnostic
systems
Carl Zeiss Meditec
AG is primarily engaged in manufacture of instruments and appliances used for
medical, surgical, dental or veterinary purposes (electro-diagnostic apparatus
such as electrocardiographs, ultrasonic diagnostic equipment, scintillation
scanners, nuclear magnetic resonance apparatus, dental drill engines,
sterilizers, ophthalmic instruments); manufacture of syringes, needles used in
medicine, mirrors, reflectors, endoscopes, etc.; manufacture of apparatus based
on the use of X-rays or alpha, beta or gamma radiation whether ornot for use in
human or animal medicine (X-ray tubes, high tension generators, control panels,
desks, screens, etc.); manufacture of medical, surgical, dental or veterinary
furniture (operating tables, hospital beds with mechanical fittings,
dentists’ chairs); and manufacture of mechano-therapy appliances, massage
apparatus, psychological testing apparatus, ozone therapy, oxygen therapy,
artificial respiration apparatus, gas masks, etc. This class also includes:
manufacture of orthopaedic appliances (crutches, surgical belts and trusses,
splints, artificial teeth, artificial limbs and other artificial parts of the
body, hearing aids, pace-makers, orthopaedic shoes, etc.).
Carl Zeiss Meditec
AG, a subsidiary of Carl Zeiss AG, is one of the world's leading suppliers of
solutions in the field of medical technology for ophthalmology. Founded as a
workshop for precision mechanics and optics in the German city of Jena in 1846,
Carl Zeiss is a leader in the optical and opto-electronic industries. The
company offers an array of solutions and products for semiconductor and
optoelectronic technology, life sciences and health care, eye care and
industrial solutions. Two microscopes from Carl Zeiss were among the winners of
prizes awarded by the United States' magazine Scientific Computing and
Instrumentation. There are more than 14,000 employees in the group. It has
offices in more than 30 countries and is represented in more than 100
countries, with production centers in Europe, Central America and Asia. Carl
Zeiss Meditec AG, maintains offices in Jena, Germany, has its own subsidiaries
in the United States and Japan.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Strategic Initiatives
Partnerships
Such recalls reduce the trust of people in company’s products and would affect sales.Industry RecognitionsCarl Zeiss Meditec has received a few awards and recognitions in the recent past, which improve the brand identity of the company. In October 2010, the company was awarded with the prestigious Spine Technology Award for its INTRABEAM system, which offers an alternative way of treating spine metastases. This system was developed in collaboration with the University of Mannheim and is used in the treatment of breast cancer. In May 2010, Carl Zeiss Meditec was honored with the red dot award for its OPMI LUMERA 700 surgical microscope, which was named the best for its excellent conception and outstanding design. These awards and recognition would enhance company's image and offers a strong customer base.New Product LaunchesThe company has launched a number of products in 2010, which helps it in catering to a diverse customer base and supporting its future revenue growth.
Source: GlobalData, February 10, 2011
|
|
Helpful |
Harmful |
|
Internal Origin |
Strengths |
Weaknesses |
|
External Origin |
Opportunities |
Threats |
Overview
Carl Zeiss Meditec AG is an integrated medical technology company focusing on two business areas, namely, ophthalmology and neuro/ENT surgery. It manufactures ophthalmic diagnostic and therapeutic products, including examination and surgical microscopes, diagnostic systems, laser surgery equipment, and intraocular lenses. The company markets and sells its products across the world. Its diversified manufacturing presence ensures that the company remains shielded from any material business interruption, if any of these sites be affected by a natural disaster or plant shutdown. By spreading the business across the globe, the company has managed to minimize the risks arising out of a specific geographical region. However, non-compliance by the company with applicable laws and regulations or failure to maintain, renew or obtain necessary permits and licenses could have an adverse effect on the company's results of operations and financial performance.
Strengths
Expanding
Operating Margin
The increase in Carl Zeiss Meditec’s top line resulted in increase in its operating profit and margin levels. The company's operating margin was 12.82% for fiscal year 2010. This was above the Medical Devices sector average* of -0.54%. A higher than sector average* operating margin may indicate efficient cost management or a strong pricing strategy by the company. It reported an operating income of EUR 86.74 million in fiscal year 2010, as compared to an operating income of EUR 76.08 million in fiscal year 2009, representing an increase of about 14%. As a result, the company’s operating margin increased 93 basis points (bps) over 2009, which may indicate management's high focus on improving profitability.
Efficient Use of
Resources
The company's return on equity (ROE) was 9.6% for fiscal year 2010. It reported a net income of EUR 54.89 million in fiscal year 2010, as compared to EUR 50.54 million in 2009, representing an increase of 8.6%. This was above the Medical Devices sector average* of -3.8%. A higher than sector average* ROE may indicate that the company is efficiently using the shareholders' money and that it is generating higher returns than other companies in the sector.
Constant Growth in
Revenues
Constant revenue growth of the company would strengthen its financial position and enable it to successfully carry out its growth and expansion plans. Carl Zeiss Meditec’s revenues grew consistently in the last five years (2006-2010). The company's total revenues during the period recorded a CAGR of 14.73%, increasing from EUR 390.56 million in 2006 to EUR 676.68 million in 2010. During fiscal year 2010, its revenues increased 5.71% from EUR 640.09 million in 2009. The growth in revenue was principally due to enhanced performance in all its operational segments.
Strong Product
Portfolio
The company has
diversified its product offerings with its presence in a number of industries
and markets. Carl Zeiss Meditec offers clinical solutions in Neurosurgery, ENT,
Ophthalmology/Optometry, Spine, Plastic &Reconstructive surgery, Dentistry,
Radiotherapy and Gynecology. The solutions offered by the company in
Ophthalmology/Optometry area include products for OR and Diagnosis. The
portfolio in OR consists of Refractive Surgery Systems, IOLs and Related Consumables,
Surgical Microscopes and Ophthalmic Lasers. Diagnosis products include Corneal
Topography, Slit Lamps, Glaucoma Diagnostics, Retinal Imaging, Optical
Biometry, Anterior Segment Imaging, and Wavefront Analysis. In Neurosurgery,
ENT, Spine, Dentistry and P&R, the products developed include surgical
microscopes, loupes, intraopeartive fluorescence and digital visualizations. In
Radiotherapy, the product developed is INTRABEAM System. This is used as
general information, for breast cancer therapy, for neurosurgery, for the
radiation oncologist, for the medical physicist and system components. In
Gynecology, the products developed include Colposcope 150FC, Colposcope,
MediLive ImageBox, MediLive MindStream, and FlexioStill & FlexioMotion.
Moreover, the company has most recognized and valuable brand name “ZEISS†in
the industry. Customers all over the world trust Carl Zeiss Meditec to supply
high quality products. A strong position in the market gives bargaining
leverage to the company.
Diversified Operational Presence
The company markets and sells its products across the world. Global presence of the company insulates it from the risk of operating in one country. The company holds six principal production facilities located in Jena, Oberkochen and Hennigsdorf, Germany; Dublin, the US; La Rochelle, France; and Suzhou, China. Also, the company has several smaller plants that belong to subsidiaries of Carl Zeiss Meditec S.A.S. in Besancon, France; Livingston, Scotland; and Mauritius. It produces devices and systems for ophthalmology in Jena and Dublin. In Oberkochen production plant, Carl Zeiss Meditec manufactures visualisation solutions for ophthalmology and neuro/ENT surgery. Further, the company’s intraocular lenses are manufactured at Hennigsdorf and La Rochelle sites. It produces viscoelastics that are used in cataract surgery at Livingston site. The two remaining manufacturing facilities of Carl Zeiss Meditec S.A.S., produces instruments and consumables to treat ophthalmic diseases. The company’s diversified manufacturing presence ensures that it remains shielded from any material business interruption, if any of these sites be affected by a natural disaster or plant shutdown. Carl Zeiss Meditec has direct presence in the world’s key markets with subsidiaries in Germany, France, Spain, North America and Japan. The company principally operates in the geographic regions of Germany, the US, Japan and Europe. During fiscal year 2010, it generated about 37.2% of its total revenues from Germany, followed by 33.5% from the US, 14.5% from Japan, and 14.8% from Europe. By spreading the business across the globe, the company has managed to minimize the risks arising out of a specific geographical region.
Weaknesses
Limited Liquidity
Position
The company's current
ratio was 3.48 at the end of fiscal year 2010. This was below the Medical
Devices sector average* of 3.92. A lower than sector average* current ratio
indicates that the company is in a weaker financial position than other
companies in the sector.
Product Callback
Product recalls
would not only have an impact on Carl Zeiss Meditec’s projected sales and
profits, but also result in negative publicity. On January 14, 2011, the
company’s US subsidiary Carl Zeiss Meditec Inc called back about 2540 units
of its VISU 200 surgical microscopes due to an error in the user manual, which
may lead to potential retina damage due to misapplied filter. In September
2009, the company recalled its Stratus OCT Model 3000 ophthalmic instruments
distributed with version 6.0.0 software due to Mis-labeled image, which leads
to a report that incorrectly labels OD or OS. Carl Zeiss Meditec also recalled
its VISULINK 532/U, a medical device designed for use in photocoagulating
ocular tissues in the treatment of diseases of the eye products. This recall
was principally due to a defective mirror coating in the device. Such recalls
reduce the trust of people in company’s products and would affect sales.
Opportunities
Growth in Vision Care Sector
The company can be
significantly benefited from the growing vision care market through its current
product portfolio and launch of innovative products. In the recent years, the
market for vision care has seen significant growth. It is estimated that over
57% of the population in the US, required vision correction. The global vision
care market was valued at USD 13.5 billion in 2009, and is expected to grow by
2.6% during 2009-2016 to reach USD 23.8 billion by 2016 according to in-house
forecasts. This forecasted growth will principally be driven by socioeconomic
factors such as ever increasing physical health consciousness, as well as
increased efforts to reduce healthcare costs. Targeted marketing programs and
product launches will ensure that the company continues to augment its market
share in the global vision care devices market.
Industry Recognitions
Carl Zeiss Meditec
has received a few awards and recognitions in the recent past, which improve
the brand identity of the company. In October 2010, the company was awarded
with the prestigious Spine Technology Award for its INTRABEAM system, which
offers an alternative way of treating spine metastases. This system was
developed in collaboration with the University of Mannheim and is used in the
treatment of breast cancer. In May 2010, Carl Zeiss Meditec was honored with
the red dot award for its OPMI LUMERA 700 surgical microscope, which was named
the best for its excellent conception and outstanding design. These awards and
recognition would enhance company's image and offers a strong customer base.
New Product Launches
The company has
launched a number of products in 2010, which helps it in catering to a diverse
customer base and supporting its future revenue growth. In October, Carl Zeiss
Meditec introduced FORUM Glaucoma Workplace, VISULAS 532s VITE Laser System,
and new indications cleared for the VisuMax Femtosecond Laser. In September,
the company launched EyeMag Smart with sports frame for use in dental practices
and microsurgery. It also introduced the multidisciplinary OPMI VARIO 700
surgical microscope, to addresses growth markets in microsurgery. In August,
Carl Zeiss Meditec introduced Smart PI software for its scanning electron
microscope. In May, the company launched a hard and software package for
scanning electronic microscopes, namely, ATLAS. It is used both in neurological
research and general histology and pathology. Additionally, in May, the company
launched LED technology for stereomicroscopes. In April, it launched VisuMax
Femtosecond Laser with ReLEx performs. This newly launched ReLEx application
enables the ophthalmic surgeons to perform a variety of complete laser vision
correction procedures using only the VisuMax Femtosecond laser. In January, the
company extended its CONTURA G2 lines of products with navigator technology.
These newly launched products provide enough opportunities for the company to
expand its market share.
Growing Aged Population
The increasing
population of people aged above 65, who consume more medical solutions than
younger people and are more prone to chronic diseases, holds significant market
potential for the company. The United Nations Population Division estimated
that the number of people over the age of 60 throughout the world will triple
to nearly 2 billion by 2050. Globally, the population of older persons is
growing at a rate of 2.6% annually. According to the United Nations Population
Division, people aged 60 are projected to account for 22% of the total world
population by 2050, up from 11% in 2009. In developed economies such as the US,
UK, France, Germany and Japan, the percentage of the 65 and older population is
in double digits and is expected to continue to grow for the next seven years.
Whilst developed countries have managed to slow down their overall population
growth, their citizens’ longevity will cause problems in the future. Such a
situation will increase the healthcare costs in those countries. The pace of
aging population is faster in developing countries than in developed countries.
Due to the large volume of the overall population in countries such as China
and India, the number of people getting older is quite high. In 2009, the
number of persons aged above 60 had increased three and a half times to 737
million. There were 12 countries with more than 10 million people aged above
60, including China (160 million), India (89 million), the US (56 million),
Japan (38 million), the Russian Federation (25 million) and Germany (21
million). By 2050, 32 countries are expected to have over 10 million people
aged above 60, including five countries with more than 50 million older people:
China (440 million), India (316 million), the US (111 million), Indonesia (72
million) and Brazil (64 million). This elderly population is expected to exert
increasing pressure on the healthcare system.
Market Growth in Emerging Economies
Emerging markets
offer a strong growth opportunity for the company, which can leverage its
strong brand and product portfolio to take advantage of rapid growth in these
markets. The demand in the core markets is falling; hence, in order to sustain
their top-line, companies are looking at tapping new markets, especially the
emerging economies. According to our in-house forecasts, medical equipment
market in emerging economies (China, India and Brazil) has grown at a CAGR of
6.5% over the last eight years to reach USD 20.8 billion in 2009, driven by
positive demographics, increased awareness of medical conditions, the
availability of treatment options, and an increase in income levels. It is
forecast to grow at a CAGR of 7.3% to reach USD 31.8 billion in 2015. The company
envisages considerable opportunity to grow as healthcare systems are modernized
and expanded in these economies.
Threats
Healthcare Reform Bill
The healthcare
reform bill signed by President Obama on March 23, 2010, requires subsidizing
healthcare reform through substantial annual excise tax on medical device sales
commencing in 2013. The significant reforms to the US healthcare system include
provisions, among other things, to impose new and increased taxes or to reduce
and limit medicare reimbursements. These initiatives will result in reduced
medical procedure volumes, impacting the volume and price levels of products
sold, increased cost level. The initiative by the government may harm business
activities, results of operations and the financial performance of Carl Zeiss
Meditec.
Regulatory Requirements
Carl Zeiss
Meditec’s products, research and development activities and manufacturing
processes are subject to various local, state, federal, foreign and
transnational laws and regulations. In the US, the FDA regulates the
introduction of new medical products, manufacturing and labeling and record
keeping procedures for such products. Receiving marketing approval for new
medical devices from the US FDA is time consuming and expensive. Products distributed
outside of the US are also subject to regulations in countries in which Carl
Zeiss Meditec operates. The company has to comply with rules brought into force
by foreign regulatory bodies, which have established different regulations
governing product standards, packaging and labeling requirements, import
restrictions, tariff regulations and tax requirements. Non-compliance by the
company with applicable laws and regulations or failure to maintain, renew or
obtain necessary permits and licenses could have an adverse effect on the
company's results of operations and financial performance.
Intense
Competition
The company’s
performance could be affected by the competitive environment prevailing in the
medical equipment sector and customer preferences. The demand for its products
depends on the competitive atmosphere, including the timely development and
introduction of new and competitive products and the company’s response to
downward pricing to sustain competition. Factors including changes in customer
order patterns, changing incentive programs or competitors’ new products can
impact the company’s competitive ability.
Rapid Technological Change
The medical device
industry is subject to various significant ongoing technological advances and
product innovation and development. Hence, in order to meet its customer’s
demands, Carl Zeiss Meditec must continuously design new, and update existing
products and invest and develop new technologies and products. The launch of
new products and technologies by the company involves a significant commitment
towards its research and development. Upon investing in these new technologies,
the company’s profits may suffer if they are not accepted in the marketplace
as anticipated. Additionally, its competitors may develop innovative
technologies and products, which might render its technology and products under
development obsolete or uncompetitive.
Cost Containment Pressures
The company’s
ability to price its devices is under threat following the increased level of
scrutiny over the cost effectiveness of treatments by government as well as
private players. The initiatives of managed care organizations and governments
to contain healthcare costs in the US led to increased emphasis on the delivery
of more cost-effective medical therapies. This could adversely affect the sales
and prices of the company’s products. Physicians, hospitals and other
healthcare providers may be reluctant to purchase the company's products if
they are not reimbursed the cost of the company's products from third-party
payers such as Medicare, Medicaid and health insurance programs. For instance,
the Centers for Medicare and Medicaid Services (CMS) have imposed restrictions
on the prices at which medical devices and physician-administered drugs used in
ophthalmic surgery are reimbursed to Medicare patients.
|
Corporate
Family |
Corporate
Structure News: |
|
|
|
|
Total Corporate Family Members: 107 |
|
|
|
|
|
|
|
|
Company
Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
Stuttgart |
Germany |
|
|
|
|
|
Subsidiary |
OBERKOCHEN |
Germany |
Scientific and Technical Instruments |
4,026.8 |
24,000 |
|
|
Subsidiary |
Jena |
Germany |
Medical Equipment and Supplies |
1,057.2 |
2,366 |
|
|
Subsidiary |
Le Pecq |
France |
Personal and Household Products |
57.6 |
88 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Medical Equipment and Supplies |
70.8 |
84 |
|
|
Carl Zeiss
Meditec Asset Management Verwaltungsgesellschaft mbH |
Subsidiary |
Jena, ThUringen |
Germany |
Rental and Leasing |
|
|
|
Subsidiary |
Jena |
Germany |
Software and Programming |
|
1,700 |
|
|
Subsidiary |
Jena |
Germany |
Scientific and Technical Instruments |
306.0 |
1,400 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
|
750 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
|
700 |
|
|
Subsidiary |
Tholey, Saarland |
Germany |
Scientific and Technical Instruments |
|
102 |
|
|
Subsidiary |
Essingen, Baden-WUrttemberg |
Germany |
Engineering Consultants |
|
40 |
|
|
Subsidiary |
Ostfildern, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
3.3 |
20 |
|
|
Subsidiary |
Wangen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
2.3 |
20 |
|
|
Subsidiary |
Wetzlar |
Germany |
Scientific and Technical Instruments |
94.6 |
500 |
|
|
Subsidiary |
Jena, ThUringen |
Germany |
Scientific and Technical Instruments |
38.4 |
90 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Electronic Instruments and Controls |
20.8 |
90 |
|
|
Subsidiary |
Wetzlar, Hessen |
Germany |
Scientific and Technical Instruments |
1.0 |
500 |
|
|
Subsidiary |
Chacao |
Venezuela |
Miscellaneous Capital Goods |
93.0 |
350 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Engineering Consultants |
91.2 |
350 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
|
320 |
|
|
Subsidiary |
Johannesburg |
South Africa |
Miscellaneous Capital Goods |
8.0 |
200 |
|
|
Subsidiary |
Ljubljana |
Slovenia |
Food Processing |
47.0 |
149 |
|
|
Subsidiary |
Bangalore |
India |
Medical Equipment and Supplies |
35.0 |
113 |
|
|
Subsidiary |
Central, Hong Kong Island |
Hong Kong |
Miscellaneous Capital Goods |
31.0 |
100 |
|
|
Subsidiary |
São Paulo , São Paulo |
Brazil |
Biotechnology and Drugs |
25.0 |
100 |
|
|
Subsidiary |
Shanghai, Shanghai |
China |
Biotechnology and Drugs |
2.0 |
100 |
|
|
Subsidiary |
Sliedrecht, Zuid-Holland |
Netherlands |
Miscellaneous Capital Goods |
|
55 |
|
|
Joint Venture |
Bangkok, Bangkok |
Thailand |
Biotechnology and Drugs |
8.0 |
50 |
|
|
Subsidiary |
Oberkochen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
|
50 |
|
|
Subsidiary |
Singapore |
Singapore |
Miscellaneous Capital Goods |
31.0 |
39 |
|
|
Subsidiary |
Petaling Jaya, Selangor |
Malaysia |
Biotechnology and Drugs |
6.1 |
|
|
|
Subsidiary |
Zagreb |
Croatia |
Miscellaneous Capital Goods |
|
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Food Processing |
|
|
|
|
Subsidiary |
Bucharest |
Romania |
Food Processing |
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Food Processing |
|
|
|
|
Subsidiary |
Mainz |
Germany |
Construction - Supplies and Fixtures |
3,842.6 |
17,396 |
|
|
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Scientific and Technical Instruments |
723.3 |
2,700 |
|
|
Subsidiary |
Jena, ThUringen |
Germany |
Miscellaneous Capital Goods |
|
160 |
|
|
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Electronic Instruments and Controls |
|
130 |
|
|
Subsidiary |
Mitterteich |
Germany |
Personal and Household Products |
182.4 |
1,220 |
|
|
Subsidiary |
Valasske Mezirci |
Czech Republic |
Semiconductors |
487.6 |
532 |
|
|
Subsidiary |
Jena, ThUringen |
Germany |
Miscellaneous Financial Services |
75.0 |
400 |
|
|
Subsidiary |
Tokyo |
Japan |
Scientific and Technical Instruments |
147.1 |
297 |
|
|
Subsidiary |
Jena, ThUringen |
Germany |
Construction - Supplies and Fixtures |
|
260 |
|
|
Subsidiary |
Mullheim |
Germany |
Personal and Household Products |
|
200 |
|
|
Subsidiary |
ValaskÃe Mezirci |
Czech Republic |
Personal and Household Products |
38.3 |
195 |
|
|
Subsidiary |
San Luis Potosi, San Luis Potosi |
Mexico |
Miscellaneous Capital Goods |
0.1 |
175 |
|
|
Subsidiary |
Iztacalco, Federal District |
Mexico |
Miscellaneous Capital Goods |
16.0 |
100 |
|
|
Subsidiary |
Cota, Cundinamarca, Apartado, Cundinamarca |
Colombia |
Miscellaneous Capital Goods |
15.0 |
100 |
|
|
Subsidiary |
Singapore |
Singapore |
Miscellaneous Capital Goods |
|
100 |
|
|
Subsidiary |
Bangkok, Bangkok |
Thailand |
Construction - Supplies and Fixtures |
|
|
|
|
Subsidiary |
Jakarta, Bali |
Indonesia |
Containers and Packaging |
|
|
|
|
Subsidiary |
Casteljaloux |
France |
Containers and Packaging |
7.8 |
74 |
|
|
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Construction - Raw Materials |
89.6 |
32 |
|
|
Subsidiary |
Frenchs Forest, NSW |
Australia |
Miscellaneous Capital Goods |
1.7 |
13 |
|
|
Subsidiary |
Hsinchuang City, Taipei Hsien |
Taiwan |
Miscellaneous Capital Goods |
|
10 |
|
|
Subsidiary |
Elmsford, NY |
United States |
Personal and Household Products |
495.0 |
9 |
|
|
Branch |
Duryea, PA |
United States |
Retail (Home Improvement) |
60.0 |
425 |
|
|
Subsidiary |
Elmsford, NY |
United States |
Miscellaneous Fabricated Products |
|
400 |
|
|
Subsidiary |
Sweetwater, TN |
United States |
Personal and Household Products |
140.0 |
350 |
|
|
Branch |
Vincennes, IN |
United States |
Personal and Household Products |
74.1 |
300 |
|
|
Branch |
Madisonville, KY |
United States |
Furniture and Fixtures |
47.3 |
85 |
|
|
Subsidiary |
Southbridge, MA |
United States |
Chemicals - Plastics and Rubber |
20.0 |
350 |
|
|
Branch |
Elmsford, NY |
United States |
Construction Services |
105.6 |
200 |
|
|
Subsidiary |
Lebanon, PA |
United States |
Personal and Household Products |
15.0 |
135 |
|
|
Subsidiary |
Dalton, GA |
United States |
Appliance and Tool |
|
100 |
|
|
Branch |
Cary, IL |
United States |
Electronic Instruments and Controls |
17.9 |
70 |
|
|
Subsidiary |
Louisville, KY |
United States |
Miscellaneous Fabricated Products |
|
32 |
|
|
Branch |
Vincennes, IN |
United States |
Miscellaneous Fabricated Products |
58.2 |
300 |
|
|
Subsidiary |
Louisville, KY |
United States |
Miscellaneous Fabricated Products |
|
32 |
|
|
Subsidiary |
Rocklin, CA |
United States |
Personal and Household Products |
|
20 |
|
|
Branch |
Albuquerque, NM |
United States |
Miscellaneous Capital Goods |
57.9 |
100 |
|
|
Subsidiary |
Rio de Janeiro |
Brazil |
Personal and Household Products |
|
13 |
|
|
Subsidiary |
Westborough, MA |
United States |
Miscellaneous Fabricated Products |
|
5 |
|
|
Subsidiary |
Clichy |
France |
Construction - Supplies and Fixtures |
0.2 |
4 |
|
|
Subsidiary |
Pont Sur Yonne |
France |
Containers and Packaging |
28.0 |
224 |
|
|
Karmesin
GrundstUcksverwaltungsgesellschaft mbH & Co. Vermietungs KG |
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Business Services |
2.4 |
2 |
|
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Commercial Banks |
|
2 |
|
|
Subsidiary |
Alzenau |
Germany |
Electric Utilities |
125.0 |
|
|
|
Schott
(Shanghai) Precision Materials & Equipment International Trading Co Ltd |
Subsidiary |
Shanghai |
China |
Construction - Supplies and Fixtures |
|
|
|
Subsidiary |
Itupeva, SP |
Brazil |
Personal and Household Products |
|
|
|
|
Subsidiary |
Seoul, Seoul |
Korea, Republic of |
Construction - Supplies and Fixtures |
|
|
|
|
Subsidiary |
Aalen, Baden-WUrttemberg |
Germany |
Commercial Banks |
1,188.3 |
12,000 |
|
|
Subsidiary |
Aalen, Baden-WUrttemberg |
Germany |
Commercial Banks |
|
1,400 |
|
|
Subsidiary |
Aalen, Baden-WUrttemberg |
Germany |
Scientific and Technical Instruments |
240.2 |
1,002 |
|
|
Subsidiary |
Castiglione Olona |
Italy |
Medical Equipment and Supplies |
91.7 |
548 |
|
|
Subsidiary |
Sliedrecht, Zuid-Holland |
Netherlands |
Miscellaneous Capital Goods |
|
11 |
|
|
Subsidiary |
Setúbal |
Portugal |
Medical Equipment and Supplies |
21.7 |
133 |
|
|
Subsidiary |
Fougeres |
France |
Medical Equipment and Supplies |
|
74 |
|
|
Subsidiary |
Landshut, Bayern |
Germany |
Electronic Instruments and Controls |
|
485 |
|
|
Subsidiary |
Arese |
Italy |
Miscellaneous Capital Goods |
51.0 |
97 |
|
|
Subsidiary |
Novara |
Italy |
Business Services |
5.1 |
21 |
|
|
Subsidiary |
Culemborg, Gelderland |
Netherlands |
Construction - Supplies and Fixtures |
|
18 |
|
|
Psephit
GrundstUcksverwaltungsgesellschaft mbH & Co. Vermietungs KG |
Subsidiary |
Mainz, Rheinland-Pfalz |
Germany |
Commercial Banks |
0.4 |
1 |
|
Subsidiary |
St Louis |
France |
Miscellaneous Capital Goods |
7.1 |
|
|
|
Subsidiary |
Culemborg, Gelderland |
Netherlands |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Culemborg, Gelderland |
Netherlands |
Construction - Supplies and Fixtures |
|
|
|
|
Subsidiary |
Troisfontaines |
France |
Construction - Supplies and Fixtures |
51.1 |
430 |
|
|
Subsidiary |
Borgo A Mozzano |
Italy |
Construction - Supplies and Fixtures |
33.8 |
175 |
Competitors Report
|
CompanyName |
Location |
Employees |
Ownership |
|
Abbott Medical Optics, Inc. |
Santa Ana, California, United States |
500 |
Private |
|
Bausch & Lomb Incorporated |
|
11,000 |
Private |
|
Ciba Vision Corporation |
|
6,500 |
Private |
|
Coopervision, Inc. |
|
660 |
Private |
|
Essilor International SA |
|
42,700 |
Public |
|
HOYA CORPORATION |
|
36,547 |
Public |
|
Nidek Co., Ltd. |
Gamagori, |
1,383 |
Private |
|
SANTEN PHARMACEUTICAL CO., LTD. |
|
2,867 |
Public |
Executive report
|
Board of
Directors |
|
|
|
|
||||||
|
Chairman of the Board |
Chairman |
|
||||||
|
|||||||||
|
Chairman of the Management Board, Chief Executive Officer |
Chairman |
|
|
|||||
|
|||||||||
|
Deputy Chairman of the Supervisory Board |
Vice-Chairman |
|
|
|||||
|
|||||||||
|
Director |
Director/Board Member |
|
|
|||||
|
Director |
Director/Board Member |
|
|
|||||
|
Director |
Director/Board Member |
|
|
|||||
|
Executives |
|
|
|
|
||||||
|
Chairman of the Management Board, Chief Executive Officer |
Chief Executive Officer |
|
||||||
|
|||||||||
|
Co-Vorstandsmitglied |
Division Head Executive |
|
|
|||||
|
Member of the Supervisory Board |
Administration Executive |
|
|
|||||
|
|||||||||
|
Member of the Supervisory Board |
Administration Executive |
|
|
|||||
|
|||||||||
|
Member of the Supervisory Board |
Administration Executive |
|
|
|||||
|
|||||||||
|
Chief Sales Officer, Member of the
Management Board |
Administration Executive |
|
|
|||||
|
|||||||||
|
Director and Chief Financial Officer |
Finance Executive |
|
|
|||||
|
|||||||||
|
Leiter-Investor Relations |
Investment Executive |
|
|
|||||
|
Leiterin-Ausbildung |
Training Executive |
|
|
|||||
|
Leiter-Marketing |
Marketing Executive |
|
|
|||||
|
Leiter-EDV |
Information Executive |
|
|
|||||
|
Director of Corporate Functions |
Other |
|
|
|||||
Significant Developments
Carl Zeiss Meditec AG to Acquire Intraocular Lens and Ophthalmic Viscoelastic Devices Business of IMEX Sep 21, 2011
Carl Zeiss Meditec AG announced that it intends to acquire the intraocular lens (IOLs) and ophthalmic viscoelastic devices (OVDs) business of IMEX, Spain. This is the objective of an asset purchase agreement signed by both parties in Vienna, Austria. Until now, IMEX has been the exclusive partner of Carl Zeiss Meditec for its IOL & OVD business on the Iberian Peninsula. The purchase price is EUR 9 million plus a performance driven component of additionally EUR 8 million in case of complete achievement of certain defined targets over the period of 2.5 years.
Carl Zeiss Meditec AG Reaffirms FY 2010/2011 Guidance-Conference Call May 05, 2011
Carl Zeiss Meditec AG announced that for fiscal 2010/2011, it expects revenue to be in the range of EUR720 million to EUR750 million. According to Reuters Estimates, analysts on average are expecting the Company to report revenue of EUR738 million for fiscal 2010/2011.
Carl Zeiss Meditec AG to Distribute FY 2010 Dividend Mar 01, 2011
Carl Zeiss Meditec AG announced that it will distribute a dividend of EUR 0.55 per share for the fiscal year 2010. The dividend for the fiscal year 2010 includes a regular dividend of EUR 0.22 per share and a special dividend of EUR 0.33 per share.
Carl Zeiss Meditec AG Issues FY 2010/2011 Guidance Above Analysts' Estimates Feb 11, 2011
Carl Zeiss Meditec AG's President and Chief Executive Officer, Dr. Ludwin Monz, announced that based on the encouraging sales in the first quarter, the Company is feeling extremely optimistic about the fiscal year 2010/2011. The Company expects to achieve revenue of between EUR 720 million and EUR 750 million provided trends in the regions do not change and there is no currency-related turbulence. According to Reuters Estimates, analysts on average are expecting the Company to achieve revenue of EUR 718.02 million.
Carl Zeiss Meditec
AG's Carl Zeiss NTS, LLC Secures IARPA R&D Contract For Gas Field Ion
Source Technology Feb 07, 2011
Carl Zeiss Meditec
AG announced that it has been awarded a $22.6 million contract to develop
certain nano manufacturing and imaging applications based on its ORION Gas
Field Ion Source (GFIS) technology. The contract was awarded to US-based Carl
Zeiss NTS, LLC by the Intelligence Advanced Research Projects Activity (IARPA)
under the Circuit Analysis Tool (CAT) program. This contract is sponsored and
managed by the Air Force Research Laboratory, Wright Patterson Air Force Base.
Carl Zeiss Meditec
Announces New Dry AMD and Glaucoma Clinical Applications for Cirrus HD-OCT
Business Wire: 20
January 2012
[What follows is
the full text of the news story.]
US FDA clearance
received today on new Cirrus HD-OCT application package
DUBLIN, Calif.
& JENA, Germany--(BUSINESS WIRE)-- Carl Zeiss Meditec announced it has
added new dry age-related macular degeneration (AMD) and new glaucoma
diagnostic tools for Cirrus HD-OCT. The new Cirrus HD-OCT software version 6.0
received clearance from the US Food and Drug Administration (FDA) today.
Designedto help
ophthalmologists manage the growing number of patients with serious eye
diseases, the new Cirrus application package offers a more comprehensive
approach to disease management, delivering more thorough and more meaningful
clinical analysis within the retina and glaucoma workplaces, says Dr. Ludwin
Monz, President and CEO of Carl Zeiss Meditec AG.
The new Cirrus
HD-OCT retina application provides Advanced Retinal Pigment Epithelium (RPE)
Analysis, which enables clinicians to objectively monitor changes associated
with dry AMD. The application tracks change in RPE elevation area and volume
often associated with drusen. It also identifies and measures the area of
transparent regions in the RPE that can develop with geographic atrophy. Unlike
blue light fundus autofluorescence (FAF), Cirrus measurements are not affected
by macular pigment in the fovea and provide an objective assessment of
geographic atrophy status as part of a standard OCT exam.
Further expanding
Carl Zeiss Meditecs retina workplace, the Cirrus HD-OCT application package
also includes Enhanced Depth Imaging (EDI), which allows for better
visualization of deeper tissues, such as the choroid, enabling doctors to
better understand the role of this anatomy in retinal disease.
The new integrated
RPE Analysis software now offers clinicians the opportunity to objectively
analyze all stages of AMD, especially the progression of dry AMD. Now one
imaging technique, the Cirrus HD-OCT, can quantitate drusen and geographic
atrophy, as well as choroidal neovascularization and any elevation of the RPE
associated with wet AMD, said Dr. Philip J. Rosenfeld,Professor of Ophthalmology
at the Bascom Palmer Eye Institute and collaborator with Carl Zeiss Meditec in
developing the techniques underlying the new applications. Now we dont have to
move patients between different instruments to visualize drusen, geographic
atrophy, and CNV. These analyses will help clinicians stage and monitor disease
progression today and will be critical to managing response to therapy as new
treatments come to market.
The new Cirrus
HD-OCT application package also extends Carl Zeiss Meditecs comprehensive suite
of glaucoma diagnostic tools, adding new Ganglion Cell Analysis and Optic Nerve
Head Progression Analysis. The Ganglion Cell Analysis evaluates the thickness
of the combined ganglion cell and inner plexiform layers and compares the
results to normative data. The new software package also expands Guided
Progression Analysis (GPA) to automatically track progression of average
cup-to-disc ratio and other optic nerve head parameters.
With these new
clinical applications, Cirrus HD-OCT now spans the full spectrum of
visualization and structural assessment in glaucoma: angle assessment, central
corneal thickness measurement and analyses of retinal nerve fiber layer,
ganglion cell layer and optic nerve head.
The new software
package addresses a global market by adding user interfaces in Japanese,
Chinese, Korean, German, French, Italian and Spanish to the original English
interface. The software received its CE mark for distribution to major European
markets in November, 2011.
Brief profile
Carl Zeiss Meditec
AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock
exchange, is one of the worlds leading medical technology suppliers. The
company supplies innovative technologies and application-oriented solutions
designed to help doctors improve the quality of life of their patients. It
provides complete packages of solutions for the diagnosis and treatment of eye
diseases - including implants and consumable materials. The company creates
innovative visualisation solutions in the field of microsurgery. Carl Zeiss
Meditec's medical technology portfolio is rounded off by promising future
technologies such as intraoperative radiation therapy. In the 2010/2011 (30
September) financial year the approx. 2,400 employees generated revenue of 759 million.
The head office of
Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany
and abroad; more than 50 percent of its employees are based in the USA, Japan,
Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free
float. The remaining 65 percent are held by Carl Zeiss AG, one of the worlds
leading groups in the optical and opto-electronics industry. Carl Zeiss offers
innovative solutions for the future-oriented markets of Industrial Solutions,
Research Solutions, Medical Technology and Consumer Optics. In fiscal year
2010/11 the companys approx. 24,000 employees generated revenue of about 4.237
billion euros. Carl Zeiss AG is wholly owned by the Carl Zeiss Stiftung (Carl
Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in
Oberkochen, Germany.
Optovue and Carl Zeiss Meditec Have Reached
Settlement in Their Current Patent Infringement Disputes
Business Wire: 10 January 2012
[What follows is the full text of the news story.]
FREMONT, Calif.
& DUBLIN, Calif.--(BUSINESS WIRE)-- Optovue Inc. and Carl Zeiss Meditec
Inc. announced today that they have signed a settlement agreement resolving two
pending Federal District Court patent infringement cases. Under the terms of
the agreement, the companies dismissed all currently pending litigation and
entered into a cross-license agreement of certain issued and to be issued
patents owned or controlled by each party. The specific terms of the settlement
are confidential.
About Optovue (www.optovue.com)
Optovue Inc. is a
privately-held ophthalmic device company dedicated to working with eye care
professionals and clinical researchers to lead the commercialization of new
imaging modalities that improve diagnosis and therapy of ocular disease.
Optovue has achieved widespread market success through a combination of unique
data analysis design, a reputation for excellent customer service, and rapid
innovation of its technology in response to physician feedback. The company is
headquartered in Fremont, CA, with operations in Carlsbad, CA and European
operations in Germany.
About Carl Zeiss Meditec (www.meditec.zeiss.com)
Carl Zeiss Meditec
AG (ISIN: DE0005313704), which is listed on TecDAX of the German stock
exchange, is one of the worlds leading medical technology suppliers. The
company supplies innovative technologies and application-oriented solutions
designed to help doctors improve the quality of life of their patients. It
provides complete packages of solutions for the diagnosis and treatment of eye diseases
- including implants and consumable materials. The company creates innovative
visualisation solutions in the field of microsurgery.
The head office of
Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany
and abroad; more than 50 percent of its employees are based in the USA, Japan,
Spain and France. Sixty-five percent of Carl Zeiss Meditec shares are held by
Carl Zeiss AG. Carl Zeiss offers innovative solutions for the future-oriented
markets Medical and Research Solutions, Industrial Solutions, Eye Care and
Lifestyle Products. Carl Zeiss AG, Oberkochen, is wholly owned by the
Carl-Zeiss Foundation.
Carl Zeiss Meditec annual net income up
Datamonitor Pharmaceutical & HealthWire: 16
December 2011
[What follows is the full text of the news story.]
Carl Zeiss
Meditec, a medical technology company, has reported that net income
attributable to shareholders of the parent company for the fiscal year ended
September 30, 2011 was E66.91 million, or E0.82 per share, compared to E54.89
million, or E0.68 per share, for the fiscal year ended September 30, 2010.
Revenue for the
fiscal 2011 was E758.79 million, compared to E676.68 million for the fiscal
2010.
Gross profit for
the fiscal 2011 was E414.84 million, compared to E358.73 million for the fiscal
2010.
"Despite the
adverse general economic situation we have been able to continue our growth
course and even exceed our expectations," says Dr Ludwin Monz, President
and CEO of Carl Zeiss Meditec AG. By 2015 the company is striving for an EBIT
margin of 15%.
German Carl Zeiss Meditec raises profit in FY
2010/11
ADP Germany News: 08 December 2011
[What follows is the full text of the news story.]
(SeeNews) - Dec 8,
2011 - German medical technology group Carl Zeiss Meditec AG (ETR:AFX) managed
to book a hefty operating profit in fiscal 2010/11 despite continued
investments in the development of new products and the expansion of sales and
service structures.
For the twelve
months through September, Carl Zeiss Meditec raised its earnings before
interest and tax (EBIT) by 19.4% on the year to EUR 103.6 million (USD 138.8m).
The EBIT margin grew to 13.6% from 12.8%.
Dividend will be
raised to EUR 0.30 apiece from EUR 0.22 paid for the previous year.
The company's
consolidated revenue advanced 12.1% to EUR 758.8 million, exceeding its own
recent forecast for revenue of between EUR 720 million and EUR 750 million. The
growth was fuelled by a double-digit increase in Asia, particularly India and
China. In fiscal 2010/11, Carl Zeiss invested 11.1% of its revenue in
innovations and solutions.
The management did
not make a forecast for fiscal 2011/12. However, CEO Ludwin Monz said that the
company is comparatively resistant to economic headwinds. The company's
well-positioned sales and service organisation will help Carl Zeiss Meditec
benefit from growth in emerging economies in Asia and South America, Monz
added. By 2015 the company aims to achieve EBIT margin of 15%.
FRANCE : Carl
Zeiss Meditec France bags contract for medical equipments, pharmaceuticals and
personal care products supply contract
TendersInfo News
04 January 2012
[What follows is
the full text of the article.]
Carl Zeiss Meditec
France has received supply contract for medical equipments, pharmaceuticals and
personal care products through an open procedure method. The contracting
authority is CHU d'Angers.
Scope of work is
for provision of a radiofrequency generator for the neurosurgery department of
the University Hospital of Angers. Information about the total bids received
for this contract is not disclosed in the release. Government Procurement
Agreement (GPA) has covered this contract and information about subcontracting
is not disclosed.
Information about
electronic auction is not revealed. Financing for this contract is not done by
any community funds. The contracting authority is not purchasing on behalf of
other contracting authorities.
Carl Zeiss Meditec AG
Files Patent Application for Treatment Apparatus for Operatively Correcting
Defective Vision of an Eye, Method for Generating Control Data Therefore, and
Method for Operatively Correcting Defective Vision of an Eye
Indian Patent News
22 December 2011
[What follows is the
full text of the article.]
New Delhi, Dec. 22
-- Germany based Carl Zeiss Meditec AG filed patent application for treatment
apparatus for operatively correcting defective vision of an eye, method for
generating control data therefor, and method for operatively correcting
defective vision of an eye. The inventors are Mark Bischoff, Gregor Stobrawa
and Wilfried Bissmann.
Carl Zeiss Meditec
AG filed the patent application on May 7, 2010. The patent application number
is 1640/KOLNP/2010 A. The international classification number is A61F 9/01.
According to the
Controller General of Patents, Designs & Trade Marks, "A treatment
apparatus for operatively correcting myopia or hyperopia in an eye is described
which treatment apparatus comprises a laser device that is controlled by a
control device and that separates the corneal tissue by applying a laser beam.
wherein said control device is designed such that said laser device can be
controlled so as to emit the laser beam into the cornea such that a
lenticule-shaped volume is isolated in the cornea, the increase in distance
between the volume and the cornea producing the desired correction. Said
control device, when controlling the laser device, predefines the
lenticule-shaped volume such that said volume has a minimum thickness in a
region of between 5 to 50 [mu]m. For myopia correction, the minimum thickness
occurs on the edge of the volume, and for hyperopia correction the minimum
thickness occurs in the region of the visual axis."
About the Company
Carl Zeiss Meditec
AG is a multinational medical technology company. It manufactures tools for eye
examinations and medical lasers as well as solutions for neurosurgery,
dentistry, gynecology and oncology. Among its products are the most common
tools used by ophthalmologists and optometrists.
FRANCE : Supply of
ophthalmology equipment contract is inked by Carl Zeiss Meditec
TendersInfo News
30 September 2011
[What follows is
the full text of the article.]
Supply of
ophthalmology equipment contract is inked by Carl Zeiss Meditec. The
contracting authority is France based CHU de Bordeaux. Scope of work includes
acquisition and maintenance of an optical coherence tomography.
Bidding was done
through open procedure. The process is been covered by Government Procurement
Agreement (GPA). Information about the total bids received is not disclosed in
the release. The bidder is not selected through an electronic auction.
Sub-contracting
for third party information is not been revealed. Whether the project or
programme is financed by community funds or not is not known. CHU de Bordeaux
is not purchasing on behalf of other contracting authorities.
FRANCE : Contract
for supply of microscopes awarded to Carl Zeiss Meditec
TendersInfo News
07 June 2011
[What follows is
the full text of the article.]
Carl Zeiss Meditec
received supply contract for microscopes. The contracting authority is CHRU de
Tours.
Scope of the work
is supply of 2 operating microscopes oriented ophthalmic surgery with
consumables, accessories and maintenance (mandatory options). Information about
the total bids received for this contract is not disclosed in the release.
Information about Government Procurement Agreement (GPA) covering this contract
and sub-contracting opportunity is not been disclosed by the contracting
authority.
The award criteria
is the most economically advantageous tender in terms of technical merit -
weighting 40, clinical value - weighting 30, price - weighting 30. Information
about electronic auction is not revealed. The procedure through which this
contract is awarded is open.
GERMANY : Carl
Zeiss Meditec Vertriebs GmbH wins contract of 244 830 Euros
TendersInfo News
13 May 2011
[What follows is
the full text of the article.]
Nordwest-Krankenhaus
Sanderbusch GmbH, Germany has issued the contract of 244 830 Euros to Carl
Zeiss Meditec Vertriebs GmbH, Germany for supply of fluorescent microscopes.
Contract is awarded as per open procedure.
Initial estimated
total value of the contract was 323 392 EUR and the final contract award value
was 244 830 EUR, both includes 19% VAT. GPA has not covered this contract with
no possible sub-contracting.
Financing for this
contract is not done by any community funds. The contractor was not selected
through an electronic auction process. The contracting authority is not
purchasing on behalf of other contracting authorities.
GERMANY : Carl
Zeiss Meditec expands base by opening CAR in Bangalore
TendersInfo News
07 February 2011
[What follows is
the full text of the article.]
Carl Zeiss
Meditec, Carl Zeiss AG Group s medical technology division, expands its base by
opening Centre for Applications & Research (CAR) in Bangalore.
According to
Michael Kaschke, President & CEO of Carl Zeiss AG, this Applications &
Research centre will reinforce the company s position in India market and
invest in research and development projects.
Ludwin Monz,
President & CEO of Carl Zeiss Meditec, stated that, this centre will invest
in ophthalmology such as glaucoma, cataracts and also diabetes led eye
deficiencies. CAR will jointly work with Indian medical research institutes,
hospitals and universities to expand IP-led products and applications, medical
techniques and solutions, along with clinical applications and studies.
Annual
Profit & Loss
|
|
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.740255 |
0.73971 |
0.666382 |
|
Consolidated |
Yes |
Yes |
Yes |
|
|
|
|
|
|
Total income |
914.1 |
865.3 |
900.7 |
|
Net sales |
914.1 |
865.3 |
900.7 |
|
Other operating income |
0.7 |
2.0 |
2.4 |
|
Cost of sales |
429.5 |
429.6 |
445.3 |
|
Gross profit |
484.6 |
435.7 |
455.3 |
|
Advertising, distribution, and commercial expenses |
219.9 |
203.7 |
212.8 |
|
General expenses |
50.3 |
43.8 |
48.4 |
|
Other operating costs |
97.8 |
86.6 |
94.8 |
|
Net operating income |
117.2 |
103.7 |
101.8 |
|
Other income |
3.0 |
7.1 |
14.7 |
|
Interest payable on loans |
7.9 |
8.1 |
8.6 |
|
Total expenses |
5.1 |
-2.5 |
-11.9 |
|
Profit before tax |
112.1 |
106.3 |
113.6 |
|
Provisions |
97.2 |
84.5 |
87.8 |
|
Total taxation |
31.5 |
31.8 |
29.2 |
|
Net profit |
80.6 |
74.5 |
84.4 |
Annual Balance Sheet
Financials in: USD (mil)
|
|
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.732493 |
0.684135 |
0.711921 |
|
Consolidated |
Yes |
Yes |
Yes |
|
|
|
|
|
|
Issued capital |
111.0 |
118.9 |
114.2 |
|
Capital reserves |
428.5 |
458.8 |
440.9 |
|
Total reserves |
261.6 |
221.3 |
162.2 |
|
Total stockholders equity |
817.7 |
789.0 |
703.4 |
|
Minority interests |
36.4 |
27.7 |
17.9 |
|
Other provisions |
70.0 |
60.6 |
49.3 |
|
Provision for pensions |
19.2 |
16.6 |
16.8 |
|
Provisions and allowances |
98.2 |
91.4 |
82.1 |
|
Taxes and social security |
29.6 |
33.5 |
31.8 |
|
Total long-term liabilities |
42.0 |
47.1 |
58.1 |
|
Trade creditors |
39.2 |
33.7 |
38.5 |
|
Advances received |
5.6 |
5.3 |
4.0 |
|
Taxation and social security |
112.1 |
36.6 |
28.6 |
|
Due to group companies |
14.9 |
13.2 |
13.0 |
|
Total current liabilities |
174.2 |
105.0 |
88.3 |
|
Regularisation account |
16.3 |
70.1 |
73.5 |
|
Total liabilities (including net worth) |
1,148.4 |
1,102.7 |
1,005.5 |
|
Patents |
26.4 |
32.0 |
27.3 |
|
Goodwill |
154.4 |
166.0 |
156.9 |
|
Other intangibles |
19.9 |
23.6 |
18.8 |
|
Intangibles |
200.7 |
221.6 |
203.1 |
|
Land and buildings |
24.0 |
26.7 |
21.9 |
|
Machinery and tools |
11.9 |
14.5 |
13.4 |
|
Fixtures and equipment |
24.0 |
26.7 |
21.9 |
|
Fixed assets under construction |
1.6 |
1.0 |
2.6 |
|
Total tangible fixed assets |
54.5 |
61.7 |
54.0 |
|
Deposits |
0.5 |
0.5 |
0.5 |
|
Total financial assets |
0.6 |
0.7 |
0.7 |
|
Total non-current assets |
255.8 |
284.0 |
257.8 |
|
Net stocks and work in progress |
162.8 |
144.8 |
167.6 |
|
Trade debtors |
139.0 |
134.7 |
130.9 |
|
Other receivables |
57.1 |
160.0 |
99.7 |
|
Total receivables |
239.9 |
329.6 |
259.0 |
|
Owing from associated companies |
43.8 |
35.0 |
28.5 |
|
Cash and liquid assets |
428.0 |
292.3 |
274.6 |
|
Short-term investments |
0.1 |
0.2 |
0.0 |
|
Shares in associated companies |
0.1 |
0.2 |
0.2 |
|
Recoverable taxation |
56.7 |
47.8 |
42.5 |
|
Total current assets |
830.8 |
766.9 |
701.2 |
|
Prepaid expenses and deferred costs |
5.1 |
3.9 |
4.0 |
|
Total assets |
1,148.4 |
1,102.7 |
1,005.5 |
Annual Ratios
Financials in: USD (mil)
|
|
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.732493 |
0.684135 |
0.711921 |
|
Consolidated |
Yes |
Yes |
Yes |
|
|
|
|
|
|
Current ratio |
47.69 |
73.03 |
79.37 |
|
Acid test ratio |
38.34 |
59.24 |
60.41 |
|
Total liabilities to net worth |
0.03% |
0.02% |
0.02% |
|
Net worth to total assets |
0.07% |
0.07% |
0.07% |
|
Current liabilities to net worth |
0.02% |
0.01% |
0.01% |
|
Current liabilities to stock |
0.11% |
0.07% |
0.05% |
|
Fixed assets to net worth |
0.03% |
0.04% |
0.04% |
|
Collection period |
548.00 |
526.00 |
566.00 |
|
Stock turnover rate |
1.76 |
1.55 |
1.99 |
|
Profit margin |
0.01% |
0.01% |
0.01% |
|
Return on assets |
0.01% |
0.01% |
0.01% |
|
Shareholders' return |
0.01% |
0.01% |
0.01% |
|
Sales per employee |
31.05 |
29.20 |
28.42 |
|
Profit per employee |
2.74 |
2.51 |
2.66 |
|
Net worth |
817.7 |
789.0 |
703.4 |
|
Number of employees |
2,179 |
2,192 |
2,112 |
Annual Income Statement
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Total Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
|
|
|
|
|
|
|
Cost of Revenue |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Cost of Revenue, Total |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Gross Profit |
578.0 |
484.6 |
435.7 |
455.3 |
392.9 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
316.8 |
270.2 |
247.4 |
261.2 |
221.4 |
|
Total Selling/General/Administrative Expenses |
316.8 |
270.2 |
247.4 |
261.2 |
221.4 |
|
Research & Development |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Investment Income -
Operating |
- |
- |
- |
0.6 |
-0.1 |
|
Interest/Investment Income - Operating |
- |
- |
- |
0.6 |
-0.1 |
|
Interest Expense (Income) - Net Operating Total |
- |
- |
- |
0.6 |
-0.1 |
|
Restructuring Charge |
- |
- |
- |
0.4 |
0.0 |
|
Litigation |
- |
- |
- |
0.0 |
0.1 |
|
Loss (Gain) on Sale of Assets - Operating |
0.0 |
-0.3 |
0.2 |
-0.2 |
0.0 |
|
Other Unusual Expense (Income) |
- |
- |
- |
-0.2 |
0.0 |
|
Unusual Expense (Income) |
0.0 |
-0.3 |
0.2 |
0.0 |
0.1 |
|
Other Operating Expense |
0.0 |
0.1 |
0.6 |
0.8 |
0.1 |
|
Other, Net |
-0.5 |
-0.4 |
-1.1 |
-2.0 |
-0.8 |
|
Other Operating Expenses, Total |
-0.5 |
-0.3 |
-0.6 |
-1.2 |
-0.7 |
|
Total Operating Expense |
912.9 |
796.9 |
762.5 |
798.9 |
663.9 |
|
|
|
|
|
|
|
|
Operating Income |
144.3 |
117.2 |
102.9 |
101.8 |
93.6 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
Interest Expense, Net Non-Operating |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
Interest Income -
Non-Operating |
6.3 |
3.0 |
7.1 |
14.7 |
12.9 |
|
Investment Income -
Non-Operating |
-3.7 |
-5.1 |
0.8 |
0.0 |
0.0 |
|
Interest/Investment Income - Non-Operating |
2.6 |
-2.0 |
8.0 |
14.7 |
12.9 |
|
Interest Income (Expense) - Net Non-Operating Total |
-7.4 |
-10.0 |
-0.1 |
6.1 |
4.4 |
|
Other Non-Operating Income (Expense) |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Other, Net |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Income Before Tax |
140.5 |
112.1 |
106.3 |
113.6 |
101.2 |
|
|
|
|
|
|
|
|
Total Income Tax |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Income After Tax |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
|
|
|
|
|
|
|
Minority Interest |
-7.5 |
-6.4 |
-6.2 |
-3.3 |
-2.5 |
|
Net Income Before Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Common Excl Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Basic EPS Excl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Basic/Primary EPS Incl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Diluted EPS Excl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted EPS Incl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Dividends per Share - Common Stock Primary Issue |
0.42 |
0.74 |
0.24 |
0.27 |
0.57 |
|
Gross Dividends - Common Stock |
34.0 |
60.4 |
19.8 |
0.0 |
46.5 |
|
Interest Expense, Supplemental |
10.0 |
7.9 |
8.1 |
8.6 |
8.5 |
|
Depreciation, Supplemental |
12.0 |
12.1 |
10.4 |
0.0 |
7.7 |
|
Total Special Items |
0.0 |
-0.3 |
0.2 |
0.0 |
0.1 |
|
Normalized Income Before Tax |
140.5 |
111.8 |
106.5 |
113.7 |
101.3 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
0.0 |
-0.1 |
0.1 |
0.0 |
0.0 |
|
Inc Tax Ex Impact of Sp Items |
39.9 |
31.5 |
31.8 |
29.3 |
35.2 |
|
Normalized Income After Tax |
100.7 |
80.4 |
74.6 |
84.4 |
66.1 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
93.2 |
74.0 |
68.5 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Amort of Intangibles, Supplemental |
14.4 |
16.3 |
11.7 |
0.0 |
8.0 |
|
Rental Expenses |
12.5 |
12.2 |
12.3 |
12.4 |
9.8 |
|
Research & Development Exp, Supplemental |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Normalized EBIT |
144.3 |
116.9 |
103.0 |
102.4 |
93.5 |
|
Normalized EBITDA |
170.7 |
145.2 |
125.2 |
102.4 |
109.2 |
|
Current Tax - Domestic |
24.2 |
21.7 |
18.3 |
21.8 |
20.7 |
|
Current Tax - Foreign |
23.1 |
23.7 |
18.8 |
14.4 |
16.6 |
|
Current Tax - Total |
47.3 |
45.4 |
37.1 |
36.2 |
37.3 |
|
Deferred Tax - Domestic |
-3.8 |
-8.0 |
-0.7 |
-4.2 |
4.7 |
|
Deferred Tax - Foreign |
-3.6 |
-5.8 |
-4.6 |
-2.7 |
-6.8 |
|
Deferred Tax - Total |
-7.4 |
-13.8 |
-5.3 |
-6.9 |
-2.1 |
|
Income Tax - Total |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Interest Cost - Domestic |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Service Cost - Domestic |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Expected Return on Assets - Domestic |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
|
Actuarial Gains and Losses - Domestic |
0.9 |
0.9 |
0.5 |
0.2 |
-0.7 |
|
Domestic Pension Plan Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Total Pension Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Discount Rate - Domestic |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Discount Rate - Foreign |
- |
- |
1.50% |
1.50% |
1.70% |
|
Expected Rate of Return - Domestic |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Expected Rate of Return - Foreign |
7.50% |
7.50% |
7.50% |
8.00% |
8.00% |
|
Compensation Rate - Domestic |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Compensation Rate - Foreign |
- |
- |
2.54% |
3.50% |
3.50% |
|
Pension Payment Rate - Domestic |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Pension Payment Rate - Foreign |
- |
- |
2.54% |
3.80% |
3.80% |
|
Total Plan Interest Cost |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Total Plan Service Cost |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Total Plan Expected Return |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
Annual Balance Sheet
Financials in: USD (mil)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.732493 |
0.684135 |
0.711921 |
0.703161 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash |
6.6 |
31.2 |
18.8 |
- |
- |
|
Cash & Equivalents |
254.6 |
396.8 |
273.5 |
274.6 |
309.9 |
|
Short Term Investments |
147.7 |
0.3 |
0.2 |
0.0 |
7.2 |
|
Cash and Short Term Investments |
408.9 |
428.3 |
292.5 |
274.6 |
317.1 |
|
Accounts Receivable -
Trade, Gross |
187.4 |
142.0 |
142.8 |
139.1 |
150.6 |
|
Provision for Doubtful
Accounts |
-6.6 |
-8.1 |
-9.4 |
-11.9 |
-13.2 |
|
Trade Accounts Receivable - Net |
235.7 |
178.0 |
168.6 |
155.7 |
159.5 |
|
Other Receivables |
26.4 |
51.3 |
150.9 |
92.0 |
88.6 |
|
Total Receivables, Net |
262.1 |
229.3 |
319.5 |
247.7 |
248.0 |
|
Inventories - Finished Goods |
118.3 |
116.0 |
103.4 |
119.5 |
100.4 |
|
Inventories - Work In Progress |
26.0 |
21.0 |
20.9 |
24.0 |
23.7 |
|
Inventories - Raw Materials |
67.9 |
57.1 |
48.9 |
50.8 |
44.9 |
|
Inventories - Other |
-32.9 |
-31.4 |
-28.5 |
-26.7 |
-25.2 |
|
Total Inventory |
179.3 |
162.8 |
144.8 |
167.6 |
143.9 |
|
Prepaid Expenses |
9.1 |
6.4 |
4.0 |
- |
- |
|
Restricted Cash - Current |
- |
- |
- |
- |
0.0 |
|
Other Current Assets |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Other Current Assets, Total |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Total Current Assets |
859.8 |
829.2 |
767.9 |
700.3 |
722.0 |
|
|
|
|
|
|
|
|
Land/Improvements |
46.6 |
45.5 |
46.6 |
39.3 |
39.7 |
|
Machinery/Equipment |
90.3 |
84.3 |
85.3 |
73.6 |
55.5 |
|
Construction in
Progress |
2.8 |
1.6 |
1.0 |
2.6 |
0.9 |
|
Property/Plant/Equipment - Gross |
139.7 |
131.4 |
132.9 |
115.5 |
96.1 |
|
Accumulated Depreciation |
-85.4 |
-77.0 |
-71.3 |
-61.5 |
-51.2 |
|
Property/Plant/Equipment - Net |
54.3 |
54.5 |
61.7 |
54.0 |
44.8 |
|
Goodwill, Net |
151.9 |
154.4 |
166.0 |
156.9 |
147.5 |
|
Intangibles - Gross |
107.4 |
108.3 |
103.8 |
- |
- |
|
Accumulated Intangible Amortization |
-75.0 |
-62.0 |
-48.2 |
- |
- |
|
Intangibles, Net |
32.4 |
46.3 |
55.6 |
46.2 |
31.2 |
|
LT Investment - Affiliate Companies |
0.0 |
0.1 |
0.2 |
0.2 |
0.0 |
|
LT Investments - Other |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Long Term Investments |
0.5 |
0.6 |
0.7 |
0.7 |
0.5 |
|
Note Receivable - Long Term |
3.7 |
5.0 |
1.3 |
3.7 |
2.3 |
|
Deferred Income Tax - Long Term Asset |
61.1 |
56.7 |
47.8 |
42.5 |
40.8 |
|
Other Long Term Assets |
0.2 |
1.7 |
1.7 |
1.2 |
1.1 |
|
Other Long Term Assets, Total |
61.3 |
58.4 |
49.5 |
43.8 |
41.9 |
|
Total Assets |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Accounts Payable |
56.9 |
54.0 |
47.0 |
51.5 |
52.6 |
|
Accrued Expenses |
91.3 |
87.8 |
64.1 |
56.4 |
48.0 |
|
Notes Payable/Short Term Debt |
7.9 |
4.6 |
2.6 |
3.0 |
0.9 |
|
Current Portion - Long Term Debt/Capital Leases |
2.7 |
2.5 |
15.5 |
2.8 |
15.8 |
|
Customer Advances |
6.3 |
5.6 |
19.9 |
- |
- |
|
Income Taxes Payable |
8.2 |
16.9 |
11.9 |
5.2 |
6.6 |
|
Other Payables |
8.0 |
14.0 |
10.4 |
10.7 |
13.4 |
|
Other Current Liabilities |
50.0 |
52.6 |
48.7 |
71.9 |
79.5 |
|
Other Current liabilities, Total |
72.6 |
89.1 |
90.8 |
87.8 |
99.6 |
|
Total Current Liabilities |
231.3 |
238.0 |
219.9 |
201.4 |
216.9 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.4 |
13.6 |
26.4 |
18.7 |
|
Capital Lease Obligations |
20.7 |
22.8 |
24.7 |
26.1 |
27.9 |
|
Total Long Term Debt |
32.3 |
35.2 |
38.3 |
52.4 |
46.6 |
|
Total Debt |
42.9 |
42.2 |
56.4 |
58.2 |
63.3 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Deferred Income Tax |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Minority Interest |
47.0 |
36.4 |
27.7 |
17.9 |
13.7 |
|
Reserves |
17.4 |
20.5 |
15.8 |
9.7 |
5.7 |
|
Pension Benefits - Underfunded |
17.8 |
19.2 |
16.6 |
16.8 |
16.0 |
|
Other Long Term Liabilities |
8.5 |
8.9 |
8.8 |
5.7 |
4.6 |
|
Other Liabilities, Total |
43.7 |
48.6 |
41.1 |
32.3 |
26.3 |
|
Total Liabilities |
360.2 |
367.1 |
341.3 |
320.0 |
319.6 |
|
|
|
|
|
|
|
|
Common Stock |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Common Stock |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Additional Paid-In Capital |
421.1 |
428.5 |
458.8 |
440.9 |
446.4 |
|
Retained Earnings (Accumulated Deficit) |
286.9 |
261.6 |
221.3 |
162.2 |
137.1 |
|
Other Comprehensive Income |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Other Equity, Total |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Total Equity |
803.7 |
781.3 |
761.3 |
685.5 |
670.7 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Employees |
2,366 |
2,189 |
2,147 |
2,152 |
1,929 |
|
Accumulated Intangible Amort, Suppl. |
75.0 |
62.0 |
48.2 |
35.1 |
27.3 |
|
Deferred Revenue - Current |
6.3 |
5.6 |
5.3 |
4.0 |
- |
|
Total Long Term Debt, Supplemental |
12.2 |
12.8 |
27.2 |
27.6 |
33.1 |
|
Long Term Debt Maturing within 1 Year |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
Long Term Debt Maturing in Year 2 |
8.5 |
0.4 |
0.4 |
13.3 |
0.4 |
|
Long Term Debt Maturing in Year 3 |
0.5 |
8.5 |
0.4 |
0.4 |
13.4 |
|
Long Term Debt Maturing in Year 4 |
0.6 |
0.5 |
9.1 |
0.4 |
0.4 |
|
Long Term Debt Maturing in Year 5 |
0.6 |
0.5 |
0.5 |
8.7 |
0.4 |
|
Long Term Debt Maturing in Year 6 |
0.6 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Long Term Debt Maturing in 2-3 Years |
9.1 |
8.9 |
0.9 |
13.7 |
13.8 |
|
Long Term Debt Maturing in 4-5 Years |
1.2 |
1.0 |
9.6 |
9.1 |
0.8 |
|
Long Term Debt Matur. in Year 6 & Beyond |
1.5 |
2.5 |
3.2 |
3.5 |
4.1 |
|
Total Capital Leases, Supplemental |
22.8 |
24.8 |
26.6 |
27.5 |
29.4 |
|
Capital Lease Payments Due in Year 1 |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Capital Lease Payments Due in Year 2 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 3 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 4 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 5 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in 2-3 Years |
5.4 |
4.8 |
4.3 |
4.0 |
3.6 |
|
Capital Lease Payments Due in 4-5 Years |
5.4 |
4.8 |
4.3 |
4.0 |
3.6 |
|
Cap. Lease Pymts. Due in Year 6 & Beyond |
9.9 |
13.1 |
16.1 |
18.1 |
20.7 |
|
Total Operating Leases, Supplemental |
31.9 |
19.1 |
25.2 |
24.8 |
13.1 |
|
Operating Lease Payments Due in Year 1 |
10.5 |
7.3 |
6.7 |
6.6 |
4.4 |
|
Operating Lease Payments Due in Year 2 |
3.5 |
2.7 |
8.3 |
7.8 |
4.1 |
|
Operating Lease Payments Due in Year 3 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Payments Due in Year 4 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Payments Due in Year 5 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Pymts. Due in 2-3 Years |
6.9 |
5.5 |
11.0 |
10.4 |
5.4 |
|
Operating Lease Pymts. Due in 4-5 Years |
6.9 |
5.5 |
5.5 |
5.2 |
2.7 |
|
Oper. Lse. Pymts. Due in Year 6 & Beyond |
7.5 |
0.9 |
2.0 |
2.6 |
0.6 |
|
Pension Obligation - Domestic |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Plan Assets - Domestic |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
|
Funded Status - Domestic |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Total Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Discount Rate - Domestic |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Discount Rate - Foreign |
- |
- |
1.50% |
1.50% |
1.70% |
|
Expected Rate of Return - Domestic |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Expected Rate of Return - Foreign |
7.50% |
7.50% |
7.50% |
8.00% |
8.00% |
|
Compensation Rate - Domestic |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Compensation Rate - Foreign |
- |
- |
2.54% |
3.50% |
3.50% |
|
Pension Payment Rate - Domestic |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Pension Payment Rate - Foreign |
- |
- |
2.54% |
3.80% |
3.80% |
|
Net Domestic Pension Assets |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Net Assets Recognized on Balance Sheet |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Equity % - Domestic |
23.54% |
20.69% |
27.39% |
18.38% |
33.82% |
|
Debt Securities % - Domestic |
53.66% |
56.50% |
55.14% |
54.09% |
39.97% |
|
Private Investments % - Domestic |
8.51% |
7.80% |
13.70% |
23.25% |
14.70% |
|
Other Investments % - Domestic |
14.29% |
15.01% |
3.77% |
- |
- |
|
Total Plan Obligations |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Total Plan Assets |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
Annual Cash Flows
Financials in: USD (mil)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
Depreciation |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Depreciation/Depletion |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Unusual Items |
1.1 |
-1.9 |
-0.1 |
-0.4 |
0.9 |
|
Other Non-Cash Items |
3.7 |
4.9 |
1.0 |
-6.1 |
2.5 |
|
Non-Cash Items |
4.8 |
3.0 |
0.9 |
-6.5 |
3.4 |
|
Accounts Receivable |
-57.1 |
-17.6 |
-2.7 |
5.4 |
-10.0 |
|
Inventories |
-21.2 |
-22.6 |
27.9 |
-19.9 |
-21.9 |
|
Other Assets |
4.3 |
1.5 |
-6.9 |
4.3 |
-2.7 |
|
Accounts Payable |
1.1 |
7.2 |
-7.6 |
-8.0 |
4.1 |
|
Taxes Payable |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Other Liabilities |
7.1 |
19.5 |
5.4 |
10.7 |
10.1 |
|
Other Operating Cash Flow |
-53.6 |
-43.4 |
-27.2 |
-36.5 |
-25.4 |
|
Changes in Working Capital |
-79.5 |
-23.8 |
20.6 |
-14.7 |
-10.6 |
|
Cash from Operating Activities |
52.3 |
88.1 |
118.1 |
82.3 |
74.6 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-8.0 |
-6.2 |
-14.0 |
-11.4 |
-6.8 |
|
Purchase/Acquisition of Intangibles |
-1.0 |
-9.5 |
-8.2 |
-8.2 |
-2.1 |
|
Capital Expenditures |
-9.0 |
-15.8 |
-22.2 |
-19.5 |
-8.8 |
|
Acquisition of Business |
- |
0.0 |
-15.7 |
-32.1 |
-10.9 |
|
Sale of Business |
0.0 |
5.4 |
- |
0.0 |
-0.2 |
|
Sale of Fixed Assets |
0.8 |
1.0 |
0.6 |
1.2 |
0.2 |
|
Purchase of Investments |
-159.3 |
-2.1 |
-4.1 |
4.3 |
-10.8 |
|
Other Investing Cash Flow |
- |
- |
0.0 |
9.0 |
6.2 |
|
Other Investing Cash Flow Items, Total |
-158.5 |
4.3 |
-19.2 |
-17.7 |
-15.4 |
|
Cash from Investing Activities |
-167.5 |
-11.4 |
-41.4 |
-37.2 |
-24.3 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-62.3 |
-19.9 |
-19.8 |
-52.5 |
-24.0 |
|
Financing Cash Flow Items |
-62.3 |
-19.9 |
-19.8 |
-52.5 |
-24.0 |
|
Sale/Issuance of
Common |
- |
- |
- |
0.0 |
232.1 |
|
Repurchase/Retirement
of Common |
- |
- |
- |
0.0 |
0.0 |
|
Common Stock, Net |
- |
- |
- |
0.0 |
232.1 |
|
Issuance (Retirement) of Stock, Net |
- |
- |
- |
0.0 |
232.1 |
|
Short Term Debt
Reduction |
0.1 |
0.0 |
-0.2 |
-2.3 |
0.0 |
|
Short Term Debt, Net |
0.1 |
0.0 |
-0.2 |
-2.3 |
-2.4 |
|
Long Term Debt Issued |
- |
- |
0.0 |
-13.2 |
0.0 |
|
Long Term Debt
Reduction |
-2.3 |
-14.0 |
-2.2 |
-4.1 |
-1.6 |
|
Long Term Debt, Net |
6.7 |
94.1 |
-50.6 |
-19.8 |
-26.9 |
|
Issuance (Retirement) of Debt, Net |
6.8 |
94.1 |
-50.8 |
-22.1 |
-29.3 |
|
Cash from Financing Activities |
-55.5 |
74.3 |
-70.6 |
-74.6 |
178.9 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
2.4 |
0.0 |
-4.2 |
-1.4 |
|
Net Change in Cash |
-165.6 |
153.4 |
6.1 |
-33.7 |
227.7 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
270.2 |
264.3 |
327.0 |
62.0 |
|
Net Cash - Ending Balance |
271.2 |
423.5 |
270.4 |
293.3 |
289.8 |
|
Cash Interest Paid |
4.4 |
3.3 |
4.0 |
5.6 |
5.2 |
|
Cash Taxes Paid |
52.6 |
42.8 |
30.1 |
42.1 |
32.7 |
Annual Income Statement
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Total Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
|
|
|
|
|
|
|
Cost of Goods Sold |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Sales and Marketing |
260.7 |
219.9 |
203.7 |
212.8 |
178.7 |
|
General/Admin. |
56.1 |
50.3 |
43.8 |
48.4 |
42.7 |
|
Research/Development |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Other Operating Income |
-0.5 |
-0.4 |
-1.1 |
-2.0 |
-0.8 |
|
Sale of Buildings |
0.0 |
-0.3 |
- |
-0.2 |
0.0 |
|
Damages |
- |
- |
- |
-0.2 |
0.0 |
|
Other Operating Expense |
0.0 |
0.1 |
0.6 |
0.8 |
0.1 |
|
Loss on Sale of Tangibles |
- |
- |
0.2 |
- |
- |
|
Integration Costs |
- |
- |
- |
0.4 |
0.0 |
|
Penalties for Non-Fulfilment |
- |
- |
- |
0.0 |
0.1 |
|
Op. For. Curr, Net |
- |
- |
- |
0.6 |
-0.1 |
|
Total Operating Expense |
912.9 |
796.9 |
762.5 |
798.9 |
663.9 |
|
|
|
|
|
|
|
|
Interest Income |
6.3 |
3.0 |
7.1 |
14.7 |
12.9 |
|
Interest Expense |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
WriteUp/Dep./Adj. |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Investments/Equity Method |
-0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Currency Gains/Losses, Net |
-3.6 |
-5.0 |
0.9 |
- |
- |
|
Net Income Before Taxes |
140.5 |
112.1 |
106.3 |
113.6 |
101.2 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Net Income After Taxes |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
|
|
|
|
|
|
|
Minority Interests |
-7.5 |
-6.4 |
-6.2 |
-3.3 |
-2.5 |
|
Net Income Before Extra. Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Com Excl ExtraOrd |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Basic EPS Excluding ExtraOrdinary Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Basic EPS Including ExtraOrdinary Item |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Diluted EPS Excluding ExtraOrd Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted EPS Including ExtraOrd Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
DPS-Bearer Shares |
0.42 |
0.74 |
0.24 |
0.27 |
0.57 |
|
Gross Dividends - Common Stock |
34.0 |
60.4 |
19.8 |
0.0 |
46.5 |
|
Normalized Income Before Taxes |
140.5 |
111.8 |
106.5 |
113.7 |
101.3 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
39.9 |
31.5 |
31.8 |
29.3 |
35.2 |
|
Normalized Income After Taxes |
100.7 |
80.4 |
74.6 |
84.4 |
66.1 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
93.2 |
74.0 |
68.5 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Interest Expense |
10.0 |
7.9 |
8.1 |
8.6 |
8.5 |
|
Research & Development Expense |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Amortisation of Intangibles |
14.4 |
16.3 |
11.7 |
0.0 |
8.0 |
|
Depreciation |
12.0 |
12.1 |
10.4 |
0.0 |
7.7 |
|
Rental Expense |
12.5 |
12.2 |
12.3 |
12.4 |
9.8 |
|
Current Tax - Domestic |
24.2 |
21.7 |
18.3 |
21.8 |
20.7 |
|
Current Tax - Foreign |
23.1 |
23.7 |
18.8 |
14.4 |
16.6 |
|
Current Tax - Total |
47.3 |
45.4 |
37.1 |
36.2 |
37.3 |
|
Deferred Tax - Domestic |
-3.8 |
-8.0 |
-0.7 |
-4.2 |
4.7 |
|
Deferred Tax - Foreign |
-3.6 |
-5.8 |
-4.6 |
-2.7 |
-6.8 |
|
Deferred Tax - Total |
-7.4 |
-13.8 |
-5.3 |
-6.9 |
-2.1 |
|
Income Tax - Total |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Current Service Cost |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Interest Expense |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Anticipated Return on Plan Assets |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
|
Recognised Actuarial Gains/Losses |
0.9 |
0.9 |
0.5 |
0.2 |
-0.7 |
|
Domestic Pension Plan Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Total Pension Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Discount Factor - Germany |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Long-Term Salary Increase - Germany |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Future Pension Increase - Germany |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Anticipated Return on Plan Assets - Germ |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Discount Rate - USA |
4.55% |
5.50% |
- |
- |
- |
|
Long-Term Salary Increase - USA |
4.00% |
3.50% |
- |
- |
- |
|
Future Pension Increase - USA |
4.00% |
4.00% |
- |
- |
- |
|
Anticipated Return on Plan Assets - USA |
7.50% |
7.50% |
- |
- |
- |
|
Discount Rate - Japan |
1.00% |
1.00% |
- |
- |
- |
|
Long-Term Salary Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Future Pension Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Discount Factor - Other |
- |
- |
1.50% |
1.50% |
1.70% |
|
Long-Term Salary Increase - Other |
- |
- |
2.54% |
3.50% |
3.50% |
|
Future Pension Increase - Other |
- |
- |
2.54% |
3.80% |
3.80% |
|
Anticipated Return on Plan Assets -Other |
- |
- |
7.50% |
8.00% |
8.00% |
Annual Balance Sheet
Financials in: USD (mil)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.732493 |
0.684135 |
0.711921 |
0.703161 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash |
6.6 |
31.2 |
18.8 |
- |
- |
|
Cash and Equivalents |
254.6 |
396.8 |
273.5 |
274.6 |
309.9 |
|
Restricted Cash |
- |
- |
- |
- |
0.0 |
|
Securities |
0.0 |
0.1 |
0.2 |
0.0 |
7.2 |
|
Treasury Receivables |
19.4 |
33.8 |
140.3 |
86.9 |
84.1 |
|
Trade Rcvbls. |
187.4 |
142.0 |
142.8 |
139.1 |
150.6 |
|
Doubtful Debts |
-6.6 |
-8.1 |
-9.4 |
-11.9 |
-13.2 |
|
Rcvbl./Affiliate |
54.5 |
43.8 |
35.0 |
28.5 |
22.1 |
|
Raw Materials |
67.9 |
57.1 |
48.9 |
50.8 |
44.9 |
|
Work in Progress |
26.0 |
21.0 |
20.9 |
24.0 |
23.7 |
|
Finished Goods |
118.3 |
116.0 |
103.4 |
119.5 |
100.4 |
|
Valuation Adj. |
-32.9 |
-31.4 |
-28.5 |
-26.7 |
-25.2 |
|
Tax Receivables |
2.3 |
11.9 |
4.6 |
5.2 |
4.4 |
|
Accounts Receivables from Subsidies |
0.4 |
0.3 |
0.3 |
- |
- |
|
Prepaid Expenses |
9.1 |
6.4 |
4.0 |
- |
- |
|
Other Receivables |
4.7 |
5.6 |
6.0 |
- |
- |
|
Other Assets |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Short Term Investments |
147.7 |
0.1 |
- |
- |
- |
|
Total Current Assets |
859.8 |
829.2 |
767.9 |
700.3 |
722.0 |
|
|
|
|
|
|
|
|
Land/Buildings |
46.6 |
45.5 |
46.6 |
39.3 |
39.7 |
|
Plant/Machinery |
25.4 |
25.6 |
26.4 |
30.0 |
18.8 |
|
Fixt./Fittings |
64.9 |
58.8 |
58.9 |
43.6 |
36.7 |
|
Construction |
2.8 |
1.6 |
1.0 |
2.6 |
0.9 |
|
Depreciation |
-85.4 |
-77.0 |
-71.3 |
-61.5 |
-51.2 |
|
Intangibles |
107.4 |
108.3 |
103.8 |
- |
- |
|
Amort. Intangib. |
-75.0 |
-62.0 |
-48.2 |
- |
- |
|
Intangibles, Net |
- |
- |
- |
46.2 |
31.2 |
|
Goodwill, Net |
151.9 |
154.4 |
166.0 |
156.9 |
147.5 |
|
Other Non-current Assets |
0.2 |
1.7 |
1.7 |
1.2 |
1.1 |
|
Shareholding |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Deferred Tax |
61.1 |
56.7 |
47.8 |
42.5 |
40.8 |
|
LT Receivables |
3.7 |
5.0 |
1.3 |
3.7 |
2.3 |
|
Investments/Equity Method |
0.0 |
0.1 |
0.2 |
0.2 |
0.0 |
|
Total Assets |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Short Term Debt |
7.9 |
4.6 |
2.6 |
3.0 |
0.9 |
|
Cur.Port.LT Debt |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
Trade Payables |
39.1 |
39.2 |
33.7 |
38.5 |
35.7 |
|
Pybl./Affiliates |
17.7 |
14.9 |
13.2 |
13.0 |
16.9 |
|
Treasury Payables |
8.0 |
14.0 |
10.4 |
10.7 |
13.4 |
|
Inc. Tax Payable |
8.2 |
16.9 |
11.9 |
5.2 |
6.6 |
|
Cur.Port. Lease |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Accrued Expenses |
63.6 |
64.1 |
55.5 |
56.4 |
48.0 |
|
Reserves |
47.0 |
49.6 |
44.8 |
39.5 |
49.1 |
|
Deferred Income/Advances |
6.3 |
5.6 |
19.9 |
- |
- |
|
Social Security, Other Taxes |
27.7 |
23.7 |
8.5 |
- |
- |
|
Other Liabs. |
3.0 |
3.0 |
3.9 |
32.4 |
30.4 |
|
Total Current Liabilities |
231.3 |
238.0 |
219.9 |
201.4 |
216.9 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.4 |
13.6 |
26.4 |
18.7 |
|
Capital Lease |
20.7 |
22.8 |
24.7 |
26.1 |
27.9 |
|
Total Long Term Debt |
32.3 |
35.2 |
38.3 |
52.4 |
46.6 |
|
|
|
|
|
|
|
|
Deferred Tax |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Other Liabs. |
8.5 |
8.9 |
8.8 |
5.7 |
4.6 |
|
Pension |
17.8 |
19.2 |
16.6 |
16.8 |
16.0 |
|
Other Provisions |
17.4 |
20.5 |
15.8 |
9.7 |
5.7 |
|
Minority Int. |
47.0 |
36.4 |
27.7 |
17.9 |
13.7 |
|
Total Liabilities |
360.2 |
367.1 |
341.3 |
320.0 |
319.6 |
|
|
|
|
|
|
|
|
Share Capital |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Add. Paid-In Cap |
421.1 |
428.5 |
458.8 |
440.9 |
446.4 |
|
Retained Earning |
286.9 |
261.6 |
221.3 |
162.2 |
137.1 |
|
Other Comp. Inc. |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Total Equity |
803.7 |
781.3 |
761.3 |
685.5 |
670.7 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders' Equity |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
S/O-Bearer Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Accumulated Intangible Amortisation |
75.0 |
62.0 |
48.2 |
35.1 |
27.3 |
|
Advance Payments |
6.3 |
5.6 |
5.3 |
4.0 |
- |
|
Full-Time Employees |
2,366 |
2,189 |
2,147 |
2,152 |
1,929 |
|
LTD < 1 Year |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
LTD < 2 Years |
8.5 |
0.4 |
0.4 |
13.3 |
0.4 |
|
LTD < 3 Years |
0.5 |
8.5 |
0.4 |
0.4 |
13.4 |
|
LTD < 4 Years |
0.6 |
0.5 |
9.1 |
0.4 |
0.4 |
|
LTD < 5 Years |
0.6 |
0.5 |
0.5 |
8.7 |
0.4 |
|
LTD < 6 Years |
0.6 |
0.5 |
0.5 |
0.5 |
0.5 |
|
LTD > 5 Years |
0.9 |
1.9 |
2.6 |
3.1 |
3.6 |
|
Total Long Term Debt, Supplemental |
12.2 |
12.8 |
27.2 |
27.6 |
33.1 |
|
Capital Lease within 1 Year |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Capital Lease from 1-5 Years |
10.8 |
9.6 |
8.6 |
7.9 |
7.2 |
|
Capital Lease over 5 Years |
9.9 |
13.1 |
16.1 |
18.1 |
20.7 |
|
Total Capital Leases |
22.8 |
24.8 |
26.6 |
27.5 |
29.4 |
|
Operating Lease within 1 Year |
10.5 |
7.3 |
6.7 |
6.6 |
4.4 |
|
Operating Lease within 2 Years |
- |
- |
8.3 |
7.8 |
4.1 |
|
Operating Lease from 1-5 Years |
13.9 |
10.9 |
8.3 |
7.8 |
4.1 |
|
Remaining |
7.5 |
0.9 |
2.0 |
2.6 |
0.6 |
|
Total Operating Leases |
31.9 |
19.1 |
25.2 |
24.8 |
13.1 |
|
Present Value of Defined Benefit Oblig. |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Fair Value of Plan Assets |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
|
Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Total Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Discount Factor - Germany |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Long-Term Salary Increase - Germany |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Future Pension Increase - Germany |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Anticipated Return on Plan Assets - Germ |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Discount Factor - USA |
4.55% |
5.50% |
- |
- |
- |
|
Long-Term Salary Increase - USA |
4.00% |
3.50% |
- |
- |
- |
|
Future Pension Increase - USA |
4.00% |
4.00% |
- |
- |
- |
|
Anticipated Return on Plan Assets - USA |
7.50% |
7.50% |
- |
- |
- |
|
Discount Factor - Japan |
1.00% |
1.00% |
- |
- |
- |
|
Long-Term Salary Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Future Pension Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Discount Factor - Other |
- |
- |
1.50% |
1.50% |
1.70% |
|
Long-Term Salary Increase - Other |
- |
- |
2.54% |
3.50% |
3.50% |
|
Future Pension Increase - Other |
- |
- |
2.54% |
3.80% |
3.80% |
|
Anticipated Return on Plan Assets -Other |
- |
- |
7.50% |
8.00% |
8.00% |
|
Net Defined Benefit Plan Assets |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Net Assets Recognized on Balance Sheet |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Assets which Cannot Be Offset |
- |
- |
- |
0.00% |
0.04% |
|
Equity Instruments |
23.54% |
20.69% |
27.39% |
18.38% |
33.82% |
|
Debt Instruments |
53.66% |
56.50% |
55.14% |
54.09% |
39.97% |
|
Cash |
8.51% |
7.80% |
13.70% |
23.25% |
14.70% |
|
Other |
14.29% |
15.01% |
3.77% |
4.27% |
11.46% |
Annual Cash Flows
Financials in: USD (mil)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Income Before Minority Interest |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
Depreciation |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Income Tax Expenses |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Interest Income/Expenses |
3.7 |
4.9 |
1.0 |
-6.1 |
-4.4 |
|
Appreciation and Write-ups |
- |
- |
- |
0.0 |
0.0 |
|
Amortisation of Financial Assets |
- |
- |
- |
0.0 |
0.0 |
|
Sale of Fixed Assets |
1.1 |
-0.3 |
-0.1 |
-0.4 |
0.9 |
|
Sale of Pharma Business |
0.0 |
-1.6 |
- |
- |
- |
|
Interest and Dividends Received |
3.3 |
2.7 |
6.9 |
11.1 |
12.5 |
|
Interest Paid |
-4.4 |
-3.3 |
-4.0 |
-5.6 |
-5.2 |
|
Income Tax Refund |
25.1 |
4.4 |
5.1 |
5.2 |
4.1 |
|
Income Tax Paid |
-77.6 |
-47.2 |
-35.3 |
-47.2 |
-36.8 |
|
Accounts Receivable |
-57.1 |
-17.6 |
-2.7 |
5.4 |
-10.0 |
|
Inventories |
-21.2 |
-22.6 |
27.9 |
-19.9 |
-21.9 |
|
Other Assets |
4.3 |
1.5 |
-6.9 |
4.3 |
-2.7 |
|
Accounts Payable |
1.1 |
7.2 |
-7.6 |
-8.0 |
4.1 |
|
Provisions and Financial Liabilities |
2.6 |
18.9 |
3.0 |
7.6 |
2.8 |
|
Other Liabilities |
4.6 |
0.7 |
2.3 |
3.2 |
7.3 |
|
Consolidation |
- |
- |
- |
0.0 |
-0.1 |
|
Pension Receivables |
- |
- |
- |
0.0 |
7.0 |
|
Results from Investments/Equity Method |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Cash from Operating Activities |
52.3 |
88.1 |
118.1 |
82.3 |
74.6 |
|
|
|
|
|
|
|
|
Restricted Cash |
- |
- |
- |
0.0 |
6.2 |
|
Purchase Fixed Asset |
-8.0 |
-6.2 |
-14.0 |
-11.4 |
-6.8 |
|
Sale of Fixed Assets |
0.8 |
1.0 |
0.6 |
1.2 |
0.2 |
|
Acquisition of Carl Zeiss SA Spain |
- |
- |
- |
0.0 |
-5.0 |
|
Acquisition of Consolidated Companies |
- |
0.0 |
-15.7 |
-32.1 |
-6.8 |
|
Proceeds/Loans |
- |
- |
- |
0.0 |
0.0 |
|
Securities |
-153.3 |
0.0 |
0.0 |
7.4 |
-6.6 |
|
Sale Subsidiary |
0.0 |
5.4 |
- |
0.0 |
-0.2 |
|
Purchase Intangibles |
-1.0 |
-9.5 |
-8.2 |
-8.2 |
-2.1 |
|
Purchase of Investment |
-6.0 |
-2.1 |
-4.1 |
-3.1 |
-4.2 |
|
Acquisition of Surgical Business |
- |
- |
- |
0.0 |
0.9 |
|
Repayment of Loans to A Former Sharehol. |
- |
- |
0.0 |
9.2 |
0.0 |
|
Repayment of Loans |
- |
- |
0.0 |
0.0 |
0.0 |
|
Investment in Interest |
- |
- |
0.0 |
-0.2 |
0.0 |
|
Cash from Investing Activities |
-167.5 |
-11.4 |
-41.4 |
-37.2 |
-24.3 |
|
|
|
|
|
|
|
|
ST Debt Repaid |
0.1 |
0.0 |
-0.2 |
-2.3 |
0.0 |
|
ST Debt, Net |
- |
- |
- |
0.0 |
-2.4 |
|
LT Debt Repaid |
-0.4 |
-0.6 |
-0.8 |
-2.6 |
-0.5 |
|
Repay. Capital Lease |
-1.9 |
-1.7 |
-1.4 |
-1.5 |
-1.2 |
|
Loans from Related Issued |
- |
- |
0.0 |
-13.2 |
0.0 |
|
Loans from Related Repayed |
0.0 |
-11.7 |
- |
- |
- |
|
Treasury Liabs., Net |
-6.0 |
4.2 |
-0.7 |
-2.7 |
-20.5 |
|
Rcvbls/Treasury, Net |
15.0 |
103.9 |
-47.8 |
0.2 |
-4.8 |
|
Capital Increase |
- |
- |
- |
0.0 |
232.1 |
|
Cost of Capital Increase |
- |
- |
- |
0.0 |
-8.8 |
|
Acquisition of Minority Interest |
0.0 |
-0.1 |
- |
- |
- |
|
Dividends Paid to Minority |
- |
- |
- |
0.0 |
0.0 |
|
Payments to CZ Medical AG |
-62.3 |
-19.8 |
-19.8 |
-52.5 |
-15.1 |
|
Treasury Stock |
- |
- |
- |
0.0 |
0.0 |
|
Cash from Financing Activities |
-55.5 |
74.3 |
-70.6 |
-74.6 |
178.9 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
2.4 |
0.0 |
-4.2 |
-1.4 |
|
Net Change in Cash |
-165.6 |
153.4 |
6.1 |
-33.7 |
227.7 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
270.2 |
264.3 |
327.0 |
62.0 |
|
Net Cash - Ending Balance |
271.2 |
423.5 |
270.4 |
293.3 |
289.8 |
|
Cash Interest Paid |
4.4 |
3.3 |
4.0 |
5.6 |
5.2 |
|
Cash Taxes Paid |
52.6 |
42.8 |
30.1 |
42.1 |
32.7 |
Financial
Health
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Annual Ratios
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Annual Income Statement
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Total Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
|
|
|
|
|
|
|
Cost of Revenue |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Cost of Revenue, Total |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Gross Profit |
578.0 |
484.6 |
435.7 |
455.3 |
392.9 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
316.8 |
270.2 |
247.4 |
261.2 |
221.4 |
|
Total Selling/General/Administrative Expenses |
316.8 |
270.2 |
247.4 |
261.2 |
221.4 |
|
Research & Development |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Investment Income -
Operating |
- |
- |
- |
0.6 |
-0.1 |
|
Interest/Investment Income - Operating |
- |
- |
- |
0.6 |
-0.1 |
|
Interest Expense (Income) - Net Operating Total |
- |
- |
- |
0.6 |
-0.1 |
|
Restructuring Charge |
- |
- |
- |
0.4 |
0.0 |
|
Litigation |
- |
- |
- |
0.0 |
0.1 |
|
Loss (Gain) on Sale of Assets - Operating |
0.0 |
-0.3 |
0.2 |
-0.2 |
0.0 |
|
Other Unusual Expense (Income) |
- |
- |
- |
-0.2 |
0.0 |
|
Unusual Expense (Income) |
0.0 |
-0.3 |
0.2 |
0.0 |
0.1 |
|
Other Operating Expense |
0.0 |
0.1 |
0.6 |
0.8 |
0.1 |
|
Other, Net |
-0.5 |
-0.4 |
-1.1 |
-2.0 |
-0.8 |
|
Other Operating Expenses, Total |
-0.5 |
-0.3 |
-0.6 |
-1.2 |
-0.7 |
|
Total Operating Expense |
912.9 |
796.9 |
762.5 |
798.9 |
663.9 |
|
|
|
|
|
|
|
|
Operating Income |
144.3 |
117.2 |
102.9 |
101.8 |
93.6 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
Interest Expense, Net Non-Operating |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
Interest Income -
Non-Operating |
6.3 |
3.0 |
7.1 |
14.7 |
12.9 |
|
Investment Income -
Non-Operating |
-3.7 |
-5.1 |
0.8 |
0.0 |
0.0 |
|
Interest/Investment Income - Non-Operating |
2.6 |
-2.0 |
8.0 |
14.7 |
12.9 |
|
Interest Income (Expense) - Net Non-Operating Total |
-7.4 |
-10.0 |
-0.1 |
6.1 |
4.4 |
|
Other Non-Operating Income (Expense) |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Other, Net |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Income Before Tax |
140.5 |
112.1 |
106.3 |
113.6 |
101.2 |
|
|
|
|
|
|
|
|
Total Income Tax |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Income After Tax |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
|
|
|
|
|
|
|
Minority Interest |
-7.5 |
-6.4 |
-6.2 |
-3.3 |
-2.5 |
|
Net Income Before Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Common Excl Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Basic EPS Excl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Basic/Primary EPS Incl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Diluted EPS Excl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted EPS Incl Extraord Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Dividends per Share - Common Stock Primary Issue |
0.42 |
0.74 |
0.24 |
0.27 |
0.57 |
|
Gross Dividends - Common Stock |
34.0 |
60.4 |
19.8 |
0.0 |
46.5 |
|
Interest Expense, Supplemental |
10.0 |
7.9 |
8.1 |
8.6 |
8.5 |
|
Depreciation, Supplemental |
12.0 |
12.1 |
10.4 |
0.0 |
7.7 |
|
Total Special Items |
0.0 |
-0.3 |
0.2 |
0.0 |
0.1 |
|
Normalized Income Before Tax |
140.5 |
111.8 |
106.5 |
113.7 |
101.3 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
0.0 |
-0.1 |
0.1 |
0.0 |
0.0 |
|
Inc Tax Ex Impact of Sp Items |
39.9 |
31.5 |
31.8 |
29.3 |
35.2 |
|
Normalized Income After Tax |
100.7 |
80.4 |
74.6 |
84.4 |
66.1 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
93.2 |
74.0 |
68.5 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Amort of Intangibles, Supplemental |
14.4 |
16.3 |
11.7 |
0.0 |
8.0 |
|
Rental Expenses |
12.5 |
12.2 |
12.3 |
12.4 |
9.8 |
|
Research & Development Exp, Supplemental |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Normalized EBIT |
144.3 |
116.9 |
103.0 |
102.4 |
93.5 |
|
Normalized EBITDA |
170.7 |
145.2 |
125.2 |
102.4 |
109.2 |
|
Current Tax - Domestic |
24.2 |
21.7 |
18.3 |
21.8 |
20.7 |
|
Current Tax - Foreign |
23.1 |
23.7 |
18.8 |
14.4 |
16.6 |
|
Current Tax - Total |
47.3 |
45.4 |
37.1 |
36.2 |
37.3 |
|
Deferred Tax - Domestic |
-3.8 |
-8.0 |
-0.7 |
-4.2 |
4.7 |
|
Deferred Tax - Foreign |
-3.6 |
-5.8 |
-4.6 |
-2.7 |
-6.8 |
|
Deferred Tax - Total |
-7.4 |
-13.8 |
-5.3 |
-6.9 |
-2.1 |
|
Income Tax - Total |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Interest Cost - Domestic |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Service Cost - Domestic |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Expected Return on Assets - Domestic |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
|
Actuarial Gains and Losses - Domestic |
0.9 |
0.9 |
0.5 |
0.2 |
-0.7 |
|
Domestic Pension Plan Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Total Pension Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Discount Rate - Domestic |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Discount Rate - Foreign |
- |
- |
1.50% |
1.50% |
1.70% |
|
Expected Rate of Return - Domestic |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Expected Rate of Return - Foreign |
7.50% |
7.50% |
7.50% |
8.00% |
8.00% |
|
Compensation Rate - Domestic |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Compensation Rate - Foreign |
- |
- |
2.54% |
3.50% |
3.50% |
|
Pension Payment Rate - Domestic |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Pension Payment Rate - Foreign |
- |
- |
2.54% |
3.80% |
3.80% |
|
Total Plan Interest Cost |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Total Plan Service Cost |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Total Plan Expected Return |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
Interim Income Statement
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
Period Length |
3 Months |
3 Months |
3 Months |
3 Months |
3 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.707825 |
0.695476 |
0.731463 |
0.736368 |
0.774922 |
|
|
|
|
|
|
|
|
Net Sales |
287.2 |
258.0 |
260.8 |
251.6 |
239.8 |
|
Revenue |
287.2 |
258.0 |
260.8 |
251.6 |
239.8 |
|
Total Revenue |
287.2 |
258.0 |
260.8 |
251.6 |
239.8 |
|
|
|
|
|
|
|
|
Cost of Revenue |
123.4 |
117.7 |
119.9 |
118.2 |
106.6 |
|
Cost of Revenue, Total |
123.4 |
117.7 |
119.9 |
118.2 |
106.6 |
|
Gross Profit |
163.8 |
140.3 |
141.0 |
133.3 |
133.2 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
88.5 |
77.0 |
76.5 |
75.0 |
73.5 |
|
Total Selling/General/Administrative Expenses |
88.5 |
77.0 |
76.5 |
75.0 |
73.5 |
|
Research & Development |
36.3 |
27.9 |
27.1 |
26.2 |
25.5 |
|
Other Operating Expense |
-0.3 |
0.3 |
0.0 |
0.0 |
-0.3 |
|
Other, Net |
-0.1 |
0.1 |
-0.1 |
-0.4 |
-0.1 |
|
Other Operating Expenses, Total |
-0.4 |
0.3 |
0.0 |
-0.4 |
-0.4 |
|
Total Operating Expense |
247.8 |
223.0 |
223.5 |
219.0 |
205.3 |
|
|
|
|
|
|
|
|
Operating Income |
39.4 |
35.0 |
37.3 |
32.6 |
34.6 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-4.3 |
-1.9 |
-2.1 |
-1.7 |
-2.6 |
|
Interest Expense, Net Non-Operating |
-4.3 |
-1.9 |
-2.1 |
-1.7 |
-2.6 |
|
Interest Income -
Non-Operating |
2.4 |
1.3 |
1.5 |
1.1 |
0.6 |
|
Investment Income -
Non-Operating |
-6.0 |
0.8 |
3.8 |
-2.3 |
2.2 |
|
Interest/Investment Income - Non-Operating |
-3.6 |
2.1 |
5.3 |
-1.2 |
2.8 |
|
Interest Income (Expense) - Net Non-Operating Total |
-7.9 |
0.2 |
3.2 |
-2.9 |
0.1 |
|
Other Non-Operating Income (Expense) |
0.9 |
0.8 |
1.0 |
0.9 |
2.6 |
|
Other, Net |
0.9 |
0.8 |
1.0 |
0.9 |
2.6 |
|
Income Before Tax |
32.5 |
36.0 |
41.5 |
30.5 |
37.3 |
|
|
|
|
|
|
|
|
Total Income Tax |
4.9 |
11.7 |
12.4 |
10.7 |
7.4 |
|
Income After Tax |
27.6 |
24.2 |
29.1 |
19.8 |
29.9 |
|
|
|
|
|
|
|
|
Minority Interest |
-2.1 |
-1.1 |
-3.1 |
-1.1 |
-1.6 |
|
Net Income Before Extraord Items |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
Net Income |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Income Available to Common Excl Extraord Items |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Basic EPS Excl Extraord Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Basic/Primary EPS Incl Extraord Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted Net Income |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Diluted EPS Excl Extraord Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted EPS Incl Extraord Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Dividends per Share - Common Stock Primary Issue |
0.42 |
0.00 |
0.00 |
0.00 |
0.71 |
|
Gross Dividends - Common Stock |
34.5 |
0.0 |
0.0 |
0.0 |
57.7 |
|
Interest Expense, Supplemental |
4.3 |
1.9 |
2.1 |
1.7 |
2.6 |
|
Depreciation, Supplemental |
6.8 |
6.0 |
6.5 |
7.0 |
10.8 |
|
Normalized Income Before Tax |
32.5 |
36.0 |
41.5 |
30.5 |
37.3 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
4.9 |
11.7 |
12.4 |
10.7 |
7.4 |
|
Normalized Income After Tax |
27.6 |
24.2 |
29.1 |
19.8 |
29.9 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted Normalized EPS |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Research & Development Exp, Supplemental |
36.3 |
27.9 |
27.1 |
26.2 |
25.5 |
|
Normalized EBIT |
39.4 |
35.0 |
37.3 |
32.6 |
34.6 |
|
Normalized EBITDA |
46.2 |
41.0 |
43.8 |
39.6 |
45.3 |
Annual Balance Sheet
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.732493 |
0.684135 |
0.711921 |
0.703161 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash |
6.6 |
31.2 |
18.8 |
- |
- |
|
Cash & Equivalents |
254.6 |
396.8 |
273.5 |
274.6 |
309.9 |
|
Short Term Investments |
147.7 |
0.3 |
0.2 |
0.0 |
7.2 |
|
Cash and Short Term Investments |
408.9 |
428.3 |
292.5 |
274.6 |
317.1 |
|
Accounts Receivable -
Trade, Gross |
187.4 |
142.0 |
142.8 |
139.1 |
150.6 |
|
Provision for Doubtful
Accounts |
-6.6 |
-8.1 |
-9.4 |
-11.9 |
-13.2 |
|
Trade Accounts Receivable - Net |
235.7 |
178.0 |
168.6 |
155.7 |
159.5 |
|
Other Receivables |
26.4 |
51.3 |
150.9 |
92.0 |
88.6 |
|
Total Receivables, Net |
262.1 |
229.3 |
319.5 |
247.7 |
248.0 |
|
Inventories - Finished Goods |
118.3 |
116.0 |
103.4 |
119.5 |
100.4 |
|
Inventories - Work In Progress |
26.0 |
21.0 |
20.9 |
24.0 |
23.7 |
|
Inventories - Raw Materials |
67.9 |
57.1 |
48.9 |
50.8 |
44.9 |
|
Inventories - Other |
-32.9 |
-31.4 |
-28.5 |
-26.7 |
-25.2 |
|
Total Inventory |
179.3 |
162.8 |
144.8 |
167.6 |
143.9 |
|
Prepaid Expenses |
9.1 |
6.4 |
4.0 |
- |
- |
|
Restricted Cash - Current |
- |
- |
- |
- |
0.0 |
|
Other Current Assets |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Other Current Assets, Total |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Total Current Assets |
859.8 |
829.2 |
767.9 |
700.3 |
722.0 |
|
|
|
|
|
|
|
|
Land/Improvements |
46.6 |
45.5 |
46.6 |
39.3 |
39.7 |
|
Machinery/Equipment |
90.3 |
84.3 |
85.3 |
73.6 |
55.5 |
|
Construction in
Progress |
2.8 |
1.6 |
1.0 |
2.6 |
0.9 |
|
Property/Plant/Equipment - Gross |
139.7 |
131.4 |
132.9 |
115.5 |
96.1 |
|
Accumulated Depreciation |
-85.4 |
-77.0 |
-71.3 |
-61.5 |
-51.2 |
|
Property/Plant/Equipment - Net |
54.3 |
54.5 |
61.7 |
54.0 |
44.8 |
|
Goodwill, Net |
151.9 |
154.4 |
166.0 |
156.9 |
147.5 |
|
Intangibles - Gross |
107.4 |
108.3 |
103.8 |
- |
- |
|
Accumulated Intangible Amortization |
-75.0 |
-62.0 |
-48.2 |
- |
- |
|
Intangibles, Net |
32.4 |
46.3 |
55.6 |
46.2 |
31.2 |
|
LT Investment - Affiliate Companies |
0.0 |
0.1 |
0.2 |
0.2 |
0.0 |
|
LT Investments - Other |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Long Term Investments |
0.5 |
0.6 |
0.7 |
0.7 |
0.5 |
|
Note Receivable - Long Term |
3.7 |
5.0 |
1.3 |
3.7 |
2.3 |
|
Deferred Income Tax - Long Term Asset |
61.1 |
56.7 |
47.8 |
42.5 |
40.8 |
|
Other Long Term Assets |
0.2 |
1.7 |
1.7 |
1.2 |
1.1 |
|
Other Long Term Assets, Total |
61.3 |
58.4 |
49.5 |
43.8 |
41.9 |
|
Total Assets |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Accounts Payable |
56.9 |
54.0 |
47.0 |
51.5 |
52.6 |
|
Accrued Expenses |
91.3 |
87.8 |
64.1 |
56.4 |
48.0 |
|
Notes Payable/Short Term Debt |
7.9 |
4.6 |
2.6 |
3.0 |
0.9 |
|
Current Portion - Long Term Debt/Capital Leases |
2.7 |
2.5 |
15.5 |
2.8 |
15.8 |
|
Customer Advances |
6.3 |
5.6 |
19.9 |
- |
- |
|
Income Taxes Payable |
8.2 |
16.9 |
11.9 |
5.2 |
6.6 |
|
Other Payables |
8.0 |
14.0 |
10.4 |
10.7 |
13.4 |
|
Other Current Liabilities |
50.0 |
52.6 |
48.7 |
71.9 |
79.5 |
|
Other Current liabilities, Total |
72.6 |
89.1 |
90.8 |
87.8 |
99.6 |
|
Total Current Liabilities |
231.3 |
238.0 |
219.9 |
201.4 |
216.9 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.4 |
13.6 |
26.4 |
18.7 |
|
Capital Lease Obligations |
20.7 |
22.8 |
24.7 |
26.1 |
27.9 |
|
Total Long Term Debt |
32.3 |
35.2 |
38.3 |
52.4 |
46.6 |
|
Total Debt |
42.9 |
42.2 |
56.4 |
58.2 |
63.3 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Deferred Income Tax |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Minority Interest |
47.0 |
36.4 |
27.7 |
17.9 |
13.7 |
|
Reserves |
17.4 |
20.5 |
15.8 |
9.7 |
5.7 |
|
Pension Benefits - Underfunded |
17.8 |
19.2 |
16.6 |
16.8 |
16.0 |
|
Other Long Term Liabilities |
8.5 |
8.9 |
8.8 |
5.7 |
4.6 |
|
Other Liabilities, Total |
43.7 |
48.6 |
41.1 |
32.3 |
26.3 |
|
Total Liabilities |
360.2 |
367.1 |
341.3 |
320.0 |
319.6 |
|
|
|
|
|
|
|
|
Common Stock |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Common Stock |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Additional Paid-In Capital |
421.1 |
428.5 |
458.8 |
440.9 |
446.4 |
|
Retained Earnings (Accumulated Deficit) |
286.9 |
261.6 |
221.3 |
162.2 |
137.1 |
|
Other Comprehensive Income |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Other Equity, Total |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Total Equity |
803.7 |
781.3 |
761.3 |
685.5 |
670.7 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Employees |
2,366 |
2,189 |
2,147 |
2,152 |
1,929 |
|
Accumulated Intangible Amort, Suppl. |
75.0 |
62.0 |
48.2 |
35.1 |
27.3 |
|
Deferred Revenue - Current |
6.3 |
5.6 |
5.3 |
4.0 |
- |
|
Total Long Term Debt, Supplemental |
12.2 |
12.8 |
27.2 |
27.6 |
33.1 |
|
Long Term Debt Maturing within 1 Year |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
Long Term Debt Maturing in Year 2 |
8.5 |
0.4 |
0.4 |
13.3 |
0.4 |
|
Long Term Debt Maturing in Year 3 |
0.5 |
8.5 |
0.4 |
0.4 |
13.4 |
|
Long Term Debt Maturing in Year 4 |
0.6 |
0.5 |
9.1 |
0.4 |
0.4 |
|
Long Term Debt Maturing in Year 5 |
0.6 |
0.5 |
0.5 |
8.7 |
0.4 |
|
Long Term Debt Maturing in Year 6 |
0.6 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Long Term Debt Maturing in 2-3 Years |
9.1 |
8.9 |
0.9 |
13.7 |
13.8 |
|
Long Term Debt Maturing in 4-5 Years |
1.2 |
1.0 |
9.6 |
9.1 |
0.8 |
|
Long Term Debt Matur. in Year 6 & Beyond |
1.5 |
2.5 |
3.2 |
3.5 |
4.1 |
|
Total Capital Leases, Supplemental |
22.8 |
24.8 |
26.6 |
27.5 |
29.4 |
|
Capital Lease Payments Due in Year 1 |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Capital Lease Payments Due in Year 2 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 3 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 4 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in Year 5 |
2.7 |
2.4 |
2.2 |
2.0 |
1.8 |
|
Capital Lease Payments Due in 2-3 Years |
5.4 |
4.8 |
4.3 |
4.0 |
3.6 |
|
Capital Lease Payments Due in 4-5 Years |
5.4 |
4.8 |
4.3 |
4.0 |
3.6 |
|
Cap. Lease Pymts. Due in Year 6 & Beyond |
9.9 |
13.1 |
16.1 |
18.1 |
20.7 |
|
Total Operating Leases, Supplemental |
31.9 |
19.1 |
25.2 |
24.8 |
13.1 |
|
Operating Lease Payments Due in Year 1 |
10.5 |
7.3 |
6.7 |
6.6 |
4.4 |
|
Operating Lease Payments Due in Year 2 |
3.5 |
2.7 |
8.3 |
7.8 |
4.1 |
|
Operating Lease Payments Due in Year 3 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Payments Due in Year 4 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Payments Due in Year 5 |
3.5 |
2.7 |
2.8 |
2.6 |
1.4 |
|
Operating Lease Pymts. Due in 2-3 Years |
6.9 |
5.5 |
11.0 |
10.4 |
5.4 |
|
Operating Lease Pymts. Due in 4-5 Years |
6.9 |
5.5 |
5.5 |
5.2 |
2.7 |
|
Oper. Lse. Pymts. Due in Year 6 & Beyond |
7.5 |
0.9 |
2.0 |
2.6 |
0.6 |
|
Pension Obligation - Domestic |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Plan Assets - Domestic |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
|
Funded Status - Domestic |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Total Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Discount Rate - Domestic |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Discount Rate - Foreign |
- |
- |
1.50% |
1.50% |
1.70% |
|
Expected Rate of Return - Domestic |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Expected Rate of Return - Foreign |
7.50% |
7.50% |
7.50% |
8.00% |
8.00% |
|
Compensation Rate - Domestic |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Compensation Rate - Foreign |
- |
- |
2.54% |
3.50% |
3.50% |
|
Pension Payment Rate - Domestic |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Pension Payment Rate - Foreign |
- |
- |
2.54% |
3.80% |
3.80% |
|
Net Domestic Pension Assets |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Net Assets Recognized on Balance Sheet |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Equity % - Domestic |
23.54% |
20.69% |
27.39% |
18.38% |
33.82% |
|
Debt Securities % - Domestic |
53.66% |
56.50% |
55.14% |
54.09% |
39.97% |
|
Private Investments % - Domestic |
8.51% |
7.80% |
13.70% |
23.25% |
14.70% |
|
Other Investments % - Domestic |
14.29% |
15.01% |
3.77% |
- |
- |
|
Total Plan Obligations |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Total Plan Assets |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
Interim Balance Sheet
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.689727 |
0.704672 |
0.745406 |
0.732493 |
|
|
|
|
|
|
|
|
Cash & Equivalents |
261.1 |
239.5 |
303.0 |
427.0 |
428.0 |
|
Short Term Investments |
0.0 |
0.0 |
0.0 |
0.2 |
0.1 |
|
Cash and Short Term Investments |
261.1 |
239.5 |
303.0 |
427.1 |
428.1 |
|
Trade Accounts Receivable - Net |
235.3 |
220.1 |
217.2 |
185.3 |
177.7 |
|
Other Receivables |
21.7 |
29.2 |
24.7 |
31.6 |
45.7 |
|
Total Receivables, Net |
257.0 |
249.3 |
241.9 |
216.8 |
223.4 |
|
Total Inventory |
179.3 |
201.1 |
187.8 |
169.7 |
162.8 |
|
Other Current Assets |
162.4 |
181.8 |
177.2 |
16.8 |
14.9 |
|
Other Current Assets, Total |
162.4 |
181.8 |
177.2 |
16.8 |
14.9 |
|
Total Current Assets |
859.8 |
871.7 |
909.9 |
830.5 |
829.2 |
|
|
|
|
|
|
|
|
Property/Plant/Equipment - Net |
54.3 |
53.6 |
53.6 |
51.9 |
54.5 |
|
Goodwill, Net |
151.9 |
162.9 |
159.7 |
152.0 |
154.4 |
|
Intangibles, Net |
32.4 |
37.3 |
39.9 |
41.6 |
46.3 |
|
LT Investment - Affiliate Companies |
0.0 |
0.0 |
0.0 |
0.0 |
0.1 |
|
LT Investments - Other |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Long Term Investments |
0.5 |
0.5 |
0.5 |
0.5 |
0.6 |
|
Note Receivable - Long Term |
3.7 |
4.7 |
4.4 |
4.4 |
5.0 |
|
Deferred Income Tax - Long Term Asset |
61.1 |
67.6 |
67.3 |
64.1 |
56.7 |
|
Other Long Term Assets |
0.2 |
2.1 |
1.8 |
1.7 |
1.7 |
|
Other Long Term Assets, Total |
61.3 |
69.7 |
69.1 |
65.7 |
58.4 |
|
Total Assets |
1,163.9 |
1,200.3 |
1,237.1 |
1,146.7 |
1,148.4 |
|
|
|
|
|
|
|
|
Accounts Payable |
64.9 |
61.8 |
74.9 |
54.4 |
68.0 |
|
Accrued Expenses |
63.6 |
73.9 |
69.7 |
59.6 |
64.1 |
|
Notes Payable/Short Term Debt |
7.9 |
3.8 |
4.3 |
5.8 |
4.6 |
|
Current Portion - Long Term Debt/Capital Leases |
2.7 |
2.6 |
2.6 |
2.6 |
2.5 |
|
Income Taxes Payable |
8.2 |
4.7 |
17.3 |
13.3 |
16.9 |
|
Other Current Liabilities |
84.0 |
95.1 |
87.8 |
93.1 |
81.9 |
|
Other Current liabilities, Total |
92.2 |
99.8 |
105.1 |
106.4 |
98.8 |
|
Total Current Liabilities |
231.3 |
242.0 |
256.6 |
228.8 |
238.0 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.9 |
12.7 |
12.0 |
12.4 |
|
Capital Lease Obligations |
20.7 |
21.4 |
22.1 |
22.3 |
22.8 |
|
Total Long Term Debt |
32.3 |
34.3 |
34.8 |
34.3 |
35.2 |
|
Total Debt |
42.9 |
40.7 |
41.7 |
42.6 |
42.2 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
5.8 |
8.2 |
8.8 |
8.9 |
8.9 |
|
Deferred Income Tax |
5.8 |
8.2 |
8.8 |
8.9 |
8.9 |
|
Minority Interest |
47.0 |
43.3 |
40.9 |
38.5 |
36.4 |
|
Reserves |
17.4 |
20.7 |
19.7 |
20.0 |
20.5 |
|
Pension Benefits - Underfunded |
17.8 |
19.8 |
17.8 |
16.1 |
19.2 |
|
Other Long Term Liabilities |
8.5 |
8.6 |
8.9 |
9.2 |
8.9 |
|
Other Liabilities, Total |
43.7 |
49.1 |
46.5 |
45.3 |
48.6 |
|
Total Liabilities |
360.2 |
376.9 |
387.6 |
355.8 |
367.1 |
|
|
|
|
|
|
|
|
Common Stock |
109.1 |
117.9 |
115.4 |
109.1 |
111.0 |
|
Common Stock |
109.1 |
117.9 |
115.4 |
109.1 |
111.0 |
|
Additional Paid-In Capital |
421.1 |
455.1 |
445.4 |
421.1 |
428.5 |
|
Retained Earnings (Accumulated Deficit) |
286.9 |
283.9 |
318.4 |
275.6 |
261.6 |
|
Other Comprehensive Income |
-13.4 |
-33.4 |
-29.7 |
-14.8 |
-19.8 |
|
Other Equity, Total |
-13.4 |
-33.4 |
-29.7 |
-14.8 |
-19.8 |
|
Total Equity |
803.7 |
823.4 |
849.5 |
790.9 |
781.3 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
1,163.9 |
1,200.3 |
1,237.1 |
1,146.7 |
1,148.4 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Treasury Shares - Common Stock Primary Issue |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Employees |
2,366 |
2,287 |
2,245 |
2,209 |
2,189 |
|
Total Long Term Debt, Supplemental |
- |
- |
6.9 |
2.6 |
2.5 |
|
Long Term Debt Maturing within 1 Year |
- |
- |
6.9 |
2.6 |
2.5 |
|
Long Term Debt Matur. in Year 6 & Beyond |
- |
- |
0.0 |
0.0 |
0.0 |
|
Total Operating Leases, Supplemental |
- |
- |
- |
- |
19.1 |
|
Operating Lease Payments Due in Year 1 |
- |
- |
- |
- |
7.3 |
|
Operating Lease Payments Due in Year 2 |
- |
- |
- |
- |
10.9 |
|
Operating Lease Pymts. Due in 2-3 Years |
- |
- |
- |
- |
10.9 |
|
Oper. Lse. Pymts. Due in Year 6 & Beyond |
- |
- |
- |
- |
0.9 |
Annual Cash Flows
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
Depreciation |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Depreciation/Depletion |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Unusual Items |
1.1 |
-1.9 |
-0.1 |
-0.4 |
0.9 |
|
Other Non-Cash Items |
3.7 |
4.9 |
1.0 |
-6.1 |
2.5 |
|
Non-Cash Items |
4.8 |
3.0 |
0.9 |
-6.5 |
3.4 |
|
Accounts Receivable |
-57.1 |
-17.6 |
-2.7 |
5.4 |
-10.0 |
|
Inventories |
-21.2 |
-22.6 |
27.9 |
-19.9 |
-21.9 |
|
Other Assets |
4.3 |
1.5 |
-6.9 |
4.3 |
-2.7 |
|
Accounts Payable |
1.1 |
7.2 |
-7.6 |
-8.0 |
4.1 |
|
Taxes Payable |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Other Liabilities |
7.1 |
19.5 |
5.4 |
10.7 |
10.1 |
|
Other Operating Cash Flow |
-53.6 |
-43.4 |
-27.2 |
-36.5 |
-25.4 |
|
Changes in Working Capital |
-79.5 |
-23.8 |
20.6 |
-14.7 |
-10.6 |
|
Cash from Operating Activities |
52.3 |
88.1 |
118.1 |
82.3 |
74.6 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-8.0 |
-6.2 |
-14.0 |
-11.4 |
-6.8 |
|
Purchase/Acquisition of Intangibles |
-1.0 |
-9.5 |
-8.2 |
-8.2 |
-2.1 |
|
Capital Expenditures |
-9.0 |
-15.8 |
-22.2 |
-19.5 |
-8.8 |
|
Acquisition of Business |
- |
0.0 |
-15.7 |
-32.1 |
-10.9 |
|
Sale of Business |
0.0 |
5.4 |
- |
0.0 |
-0.2 |
|
Sale of Fixed Assets |
0.8 |
1.0 |
0.6 |
1.2 |
0.2 |
|
Purchase of Investments |
-159.3 |
-2.1 |
-4.1 |
4.3 |
-10.8 |
|
Other Investing Cash Flow |
- |
- |
0.0 |
9.0 |
6.2 |
|
Other Investing Cash Flow Items, Total |
-158.5 |
4.3 |
-19.2 |
-17.7 |
-15.4 |
|
Cash from Investing Activities |
-167.5 |
-11.4 |
-41.4 |
-37.2 |
-24.3 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-62.3 |
-19.9 |
-19.8 |
-52.5 |
-24.0 |
|
Financing Cash Flow Items |
-62.3 |
-19.9 |
-19.8 |
-52.5 |
-24.0 |
|
Sale/Issuance of
Common |
- |
- |
- |
0.0 |
232.1 |
|
Repurchase/Retirement
of Common |
- |
- |
- |
0.0 |
0.0 |
|
Common Stock, Net |
- |
- |
- |
0.0 |
232.1 |
|
Issuance (Retirement) of Stock, Net |
- |
- |
- |
0.0 |
232.1 |
|
Short Term Debt
Reduction |
0.1 |
0.0 |
-0.2 |
-2.3 |
0.0 |
|
Short Term Debt, Net |
0.1 |
0.0 |
-0.2 |
-2.3 |
-2.4 |
|
Long Term Debt Issued |
- |
- |
0.0 |
-13.2 |
0.0 |
|
Long Term Debt
Reduction |
-2.3 |
-14.0 |
-2.2 |
-4.1 |
-1.6 |
|
Long Term Debt, Net |
6.7 |
94.1 |
-50.6 |
-19.8 |
-26.9 |
|
Issuance (Retirement) of Debt, Net |
6.8 |
94.1 |
-50.8 |
-22.1 |
-29.3 |
|
Cash from Financing Activities |
-55.5 |
74.3 |
-70.6 |
-74.6 |
178.9 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
2.4 |
0.0 |
-4.2 |
-1.4 |
|
Net Change in Cash |
-165.6 |
153.4 |
6.1 |
-33.7 |
227.7 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
270.2 |
264.3 |
327.0 |
62.0 |
|
Net Cash - Ending Balance |
271.2 |
423.5 |
270.4 |
293.3 |
289.8 |
|
Cash Interest Paid |
4.4 |
3.3 |
4.0 |
5.6 |
5.2 |
|
Cash Taxes Paid |
52.6 |
42.8 |
30.1 |
42.1 |
32.7 |
Interim Cash Flows
Standardized
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
Period Length |
12 Months |
9 Months |
6 Months |
3 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.72104 |
0.733879 |
0.736368 |
0.740255 |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
100.7 |
73.1 |
48.9 |
19.8 |
80.6 |
|
Depreciation |
26.4 |
19.6 |
13.5 |
7.0 |
28.3 |
|
Depreciation/Depletion |
26.4 |
19.6 |
13.5 |
7.0 |
28.3 |
|
Unusual Items |
1.1 |
0.4 |
0.1 |
0.4 |
-1.9 |
|
Other Non-Cash Items |
3.7 |
1.8 |
1.2 |
0.6 |
4.9 |
|
Non-Cash Items |
4.8 |
2.2 |
1.4 |
1.0 |
3.0 |
|
Accounts Receivable |
-57.1 |
-33.6 |
-34.2 |
-7.8 |
-17.6 |
|
Inventories |
-21.2 |
-33.3 |
-22.6 |
-7.5 |
-22.6 |
|
Other Assets |
4.3 |
-5.9 |
-5.7 |
-2.2 |
1.5 |
|
Accounts Payable |
1.1 |
-7.8 |
4.3 |
-14.4 |
7.2 |
|
Taxes Payable |
39.9 |
34.9 |
23.2 |
10.7 |
31.5 |
|
Other Liabilities |
7.1 |
16.1 |
4.4 |
8.2 |
19.5 |
|
Other Operating Cash Flow |
-53.6 |
-51.0 |
-24.3 |
-17.8 |
-43.4 |
|
Changes in Working Capital |
-79.5 |
-80.7 |
-54.8 |
-30.8 |
-23.8 |
|
Cash from Operating Activities |
52.3 |
14.2 |
8.9 |
-3.0 |
88.1 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-8.0 |
-4.4 |
-3.4 |
-1.2 |
-6.2 |
|
Purchase/Acquisition of Intangibles |
-1.0 |
-0.6 |
-0.4 |
0.0 |
-9.5 |
|
Capital Expenditures |
-9.0 |
-5.1 |
-3.8 |
-1.3 |
-15.8 |
|
Acquisition of Business |
- |
0.1 |
0.1 |
- |
0.0 |
|
Sale of Business |
0.0 |
0.0 |
0.0 |
0.1 |
5.4 |
|
Sale of Fixed Assets |
0.8 |
0.4 |
0.4 |
0.2 |
1.0 |
|
Purchase of Investments |
-159.3 |
-158.0 |
-155.2 |
-5.3 |
-2.1 |
|
Other Investing Cash Flow Items, Total |
-158.5 |
-157.6 |
-154.7 |
-5.0 |
4.3 |
|
Cash from Investing Activities |
-167.5 |
-162.7 |
-158.5 |
-6.3 |
-11.4 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-62.3 |
-62.0 |
0.0 |
- |
-19.9 |
|
Financing Cash Flow Items |
-62.3 |
-62.0 |
0.0 |
- |
-19.9 |
|
Short Term Debt
Reduction |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Short Term Debt, Net |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Long Term Debt
Reduction |
-2.3 |
-1.8 |
-0.8 |
-0.5 |
-14.0 |
|
Long Term Debt, Net |
6.7 |
10.1 |
17.4 |
12.7 |
94.1 |
|
Issuance (Retirement) of Debt, Net |
6.8 |
10.1 |
17.3 |
12.7 |
94.1 |
|
Cash from Financing Activities |
-55.5 |
-51.9 |
17.3 |
12.7 |
74.3 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
-5.3 |
-4.0 |
3.0 |
2.4 |
|
Net Change in Cash |
-165.6 |
-205.7 |
-136.2 |
6.5 |
153.4 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
434.8 |
427.2 |
425.8 |
270.2 |
|
Net Cash - Ending Balance |
271.2 |
229.1 |
291.0 |
432.2 |
423.5 |
|
Cash Interest Paid |
4.4 |
3.3 |
2.3 |
0.8 |
3.3 |
|
Cash Taxes Paid |
52.6 |
50.5 |
24.4 |
18.2 |
42.8 |
Annual Income Statement
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
Total Revenue |
1,057.2 |
914.1 |
865.3 |
900.7 |
757.5 |
|
|
|
|
|
|
|
|
Cost of Goods Sold |
479.2 |
429.5 |
429.6 |
445.3 |
364.6 |
|
Sales and Marketing |
260.7 |
219.9 |
203.7 |
212.8 |
178.7 |
|
General/Admin. |
56.1 |
50.3 |
43.8 |
48.4 |
42.7 |
|
Research/Development |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Other Operating Income |
-0.5 |
-0.4 |
-1.1 |
-2.0 |
-0.8 |
|
Sale of Buildings |
0.0 |
-0.3 |
- |
-0.2 |
0.0 |
|
Damages |
- |
- |
- |
-0.2 |
0.0 |
|
Other Operating Expense |
0.0 |
0.1 |
0.6 |
0.8 |
0.1 |
|
Loss on Sale of Tangibles |
- |
- |
0.2 |
- |
- |
|
Integration Costs |
- |
- |
- |
0.4 |
0.0 |
|
Penalties for Non-Fulfilment |
- |
- |
- |
0.0 |
0.1 |
|
Op. For. Curr, Net |
- |
- |
- |
0.6 |
-0.1 |
|
Total Operating Expense |
912.9 |
796.9 |
762.5 |
798.9 |
663.9 |
|
|
|
|
|
|
|
|
Interest Income |
6.3 |
3.0 |
7.1 |
14.7 |
12.9 |
|
Interest Expense |
-10.0 |
-7.9 |
-8.1 |
-8.6 |
-8.5 |
|
WriteUp/Dep./Adj. |
3.6 |
4.9 |
3.6 |
5.8 |
3.2 |
|
Investments/Equity Method |
-0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Currency Gains/Losses, Net |
-3.6 |
-5.0 |
0.9 |
- |
- |
|
Net Income Before Taxes |
140.5 |
112.1 |
106.3 |
113.6 |
101.2 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Net Income After Taxes |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
|
|
|
|
|
|
|
Minority Interests |
-7.5 |
-6.4 |
-6.2 |
-3.3 |
-2.5 |
|
Net Income Before Extra. Items |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Com Excl ExtraOrd |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Basic EPS Excluding ExtraOrdinary Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Basic EPS Including ExtraOrdinary Item |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Net Income |
93.2 |
74.1 |
68.3 |
81.1 |
63.5 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
78.0 |
|
Diluted EPS Excluding ExtraOrd Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted EPS Including ExtraOrd Items |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
DPS-Bearer Shares |
0.42 |
0.74 |
0.24 |
0.27 |
0.57 |
|
Gross Dividends - Common Stock |
34.0 |
60.4 |
19.8 |
0.0 |
46.5 |
|
Normalized Income Before Taxes |
140.5 |
111.8 |
106.5 |
113.7 |
101.3 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
39.9 |
31.5 |
31.8 |
29.3 |
35.2 |
|
Normalized Income After Taxes |
100.7 |
80.4 |
74.6 |
84.4 |
66.1 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
93.2 |
74.0 |
68.5 |
81.1 |
63.5 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Diluted Normalized EPS |
1.15 |
0.91 |
0.84 |
1.00 |
0.81 |
|
Interest Expense |
10.0 |
7.9 |
8.1 |
8.6 |
8.5 |
|
Research & Development Expense |
117.3 |
97.7 |
85.8 |
93.0 |
78.8 |
|
Amortisation of Intangibles |
14.4 |
16.3 |
11.7 |
0.0 |
8.0 |
|
Depreciation |
12.0 |
12.1 |
10.4 |
0.0 |
7.7 |
|
Rental Expense |
12.5 |
12.2 |
12.3 |
12.4 |
9.8 |
|
Current Tax - Domestic |
24.2 |
21.7 |
18.3 |
21.8 |
20.7 |
|
Current Tax - Foreign |
23.1 |
23.7 |
18.8 |
14.4 |
16.6 |
|
Current Tax - Total |
47.3 |
45.4 |
37.1 |
36.2 |
37.3 |
|
Deferred Tax - Domestic |
-3.8 |
-8.0 |
-0.7 |
-4.2 |
4.7 |
|
Deferred Tax - Foreign |
-3.6 |
-5.8 |
-4.6 |
-2.7 |
-6.8 |
|
Deferred Tax - Total |
-7.4 |
-13.8 |
-5.3 |
-6.9 |
-2.1 |
|
Income Tax - Total |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Current Service Cost |
5.9 |
3.5 |
2.1 |
3.5 |
3.3 |
|
Interest Expense |
4.1 |
3.6 |
3.4 |
3.3 |
2.8 |
|
Anticipated Return on Plan Assets |
-3.3 |
-3.1 |
-2.9 |
-3.2 |
-2.6 |
|
Recognised Actuarial Gains/Losses |
0.9 |
0.9 |
0.5 |
0.2 |
-0.7 |
|
Domestic Pension Plan Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Total Pension Expense |
7.6 |
4.8 |
3.1 |
3.8 |
2.8 |
|
Discount Factor - Germany |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Long-Term Salary Increase - Germany |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Future Pension Increase - Germany |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Anticipated Return on Plan Assets - Germ |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Discount Rate - USA |
4.55% |
5.50% |
- |
- |
- |
|
Long-Term Salary Increase - USA |
4.00% |
3.50% |
- |
- |
- |
|
Future Pension Increase - USA |
4.00% |
4.00% |
- |
- |
- |
|
Anticipated Return on Plan Assets - USA |
7.50% |
7.50% |
- |
- |
- |
|
Discount Rate - Japan |
1.00% |
1.00% |
- |
- |
- |
|
Long-Term Salary Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Future Pension Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Discount Factor - Other |
- |
- |
1.50% |
1.50% |
1.70% |
|
Long-Term Salary Increase - Other |
- |
- |
2.54% |
3.50% |
3.50% |
|
Future Pension Increase - Other |
- |
- |
2.54% |
3.80% |
3.80% |
|
Anticipated Return on Plan Assets -Other |
- |
- |
7.50% |
8.00% |
8.00% |
Interim Income Statement
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
Period Length |
3 Months |
3 Months |
3 Months |
3 Months |
3 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.707825 |
0.695476 |
0.731463 |
0.736368 |
0.774922 |
|
|
|
|
|
|
|
|
Net Sales |
287.2 |
258.0 |
260.8 |
251.6 |
239.8 |
|
Total Revenue |
287.2 |
258.0 |
260.8 |
251.6 |
239.8 |
|
|
|
|
|
|
|
|
Cost of Goods Sold |
123.4 |
117.7 |
119.9 |
118.2 |
106.6 |
|
Sales and Marketing |
73.9 |
63.5 |
62.5 |
61.0 |
59.3 |
|
General/Admin. |
14.6 |
13.6 |
14.0 |
13.9 |
14.2 |
|
Research/Development |
36.3 |
27.9 |
27.1 |
26.2 |
25.5 |
|
Other Op. Income |
-0.1 |
0.1 |
-0.1 |
-0.4 |
-0.1 |
|
Other Op. Expense |
-0.3 |
0.3 |
0.0 |
0.0 |
-0.3 |
|
Total Operating Expense |
247.8 |
223.0 |
223.5 |
219.0 |
205.3 |
|
|
|
|
|
|
|
|
Interest Income |
2.4 |
1.3 |
1.5 |
1.1 |
0.6 |
|
Interest Expense |
-4.3 |
-1.9 |
-2.1 |
-1.7 |
-2.6 |
|
FOREX Gain/Losses, Net |
-5.9 |
0.8 |
3.8 |
-2.3 |
2.2 |
|
Other Financial Result |
0.9 |
0.8 |
1.0 |
0.9 |
2.6 |
|
Investments/Equity Method |
-0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Net Income Before Taxes |
32.5 |
36.0 |
41.5 |
30.5 |
37.3 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
4.9 |
11.7 |
12.4 |
10.7 |
7.4 |
|
Net Income After Taxes |
27.6 |
24.2 |
29.1 |
19.8 |
29.9 |
|
|
|
|
|
|
|
|
Minority Interest |
-2.1 |
-1.1 |
-3.1 |
-1.1 |
-1.6 |
|
Net Income Before Extra. Items |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
Net Income |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Income Available to Com Excl ExtraOrd |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Basic EPS Excluding ExtraOrdinary Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Basic EPS Including ExtraOrdinary Item |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted Net Income |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
Diluted Weighted Average Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Diluted EPS Excluding ExtraOrd Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted EPS Including ExtraOrd Items |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
DPS-Bearer Shares |
0.42 |
0.00 |
0.00 |
0.00 |
0.71 |
|
Gross Dividends - Common Stock |
34.5 |
0.0 |
0.0 |
0.0 |
57.7 |
|
Normalized Income Before Taxes |
32.5 |
36.0 |
41.5 |
30.5 |
37.3 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
4.9 |
11.7 |
12.4 |
10.7 |
7.4 |
|
Normalized Income After Taxes |
27.6 |
24.2 |
29.1 |
19.8 |
29.9 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
25.5 |
23.2 |
26.0 |
18.7 |
28.3 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Diluted Normalized EPS |
0.31 |
0.28 |
0.32 |
0.23 |
0.35 |
|
Interest Expense |
4.3 |
1.9 |
2.1 |
1.7 |
2.6 |
|
Research & Development Expense |
36.3 |
27.9 |
27.1 |
26.2 |
25.5 |
|
Depreciation |
6.8 |
6.0 |
6.5 |
7.0 |
10.8 |
Annual Balance Sheet
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.732493 |
0.684135 |
0.711921 |
0.703161 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash |
6.6 |
31.2 |
18.8 |
- |
- |
|
Cash and Equivalents |
254.6 |
396.8 |
273.5 |
274.6 |
309.9 |
|
Restricted Cash |
- |
- |
- |
- |
0.0 |
|
Securities |
0.0 |
0.1 |
0.2 |
0.0 |
7.2 |
|
Treasury Receivables |
19.4 |
33.8 |
140.3 |
86.9 |
84.1 |
|
Trade Rcvbls. |
187.4 |
142.0 |
142.8 |
139.1 |
150.6 |
|
Doubtful Debts |
-6.6 |
-8.1 |
-9.4 |
-11.9 |
-13.2 |
|
Rcvbl./Affiliate |
54.5 |
43.8 |
35.0 |
28.5 |
22.1 |
|
Raw Materials |
67.9 |
57.1 |
48.9 |
50.8 |
44.9 |
|
Work in Progress |
26.0 |
21.0 |
20.9 |
24.0 |
23.7 |
|
Finished Goods |
118.3 |
116.0 |
103.4 |
119.5 |
100.4 |
|
Valuation Adj. |
-32.9 |
-31.4 |
-28.5 |
-26.7 |
-25.2 |
|
Tax Receivables |
2.3 |
11.9 |
4.6 |
5.2 |
4.4 |
|
Accounts Receivables from Subsidies |
0.4 |
0.3 |
0.3 |
- |
- |
|
Prepaid Expenses |
9.1 |
6.4 |
4.0 |
- |
- |
|
Other Receivables |
4.7 |
5.6 |
6.0 |
- |
- |
|
Other Assets |
0.4 |
2.5 |
7.1 |
10.4 |
13.0 |
|
Short Term Investments |
147.7 |
0.1 |
- |
- |
- |
|
Total Current Assets |
859.8 |
829.2 |
767.9 |
700.3 |
722.0 |
|
|
|
|
|
|
|
|
Land/Buildings |
46.6 |
45.5 |
46.6 |
39.3 |
39.7 |
|
Plant/Machinery |
25.4 |
25.6 |
26.4 |
30.0 |
18.8 |
|
Fixt./Fittings |
64.9 |
58.8 |
58.9 |
43.6 |
36.7 |
|
Construction |
2.8 |
1.6 |
1.0 |
2.6 |
0.9 |
|
Depreciation |
-85.4 |
-77.0 |
-71.3 |
-61.5 |
-51.2 |
|
Intangibles |
107.4 |
108.3 |
103.8 |
- |
- |
|
Amort. Intangib. |
-75.0 |
-62.0 |
-48.2 |
- |
- |
|
Intangibles, Net |
- |
- |
- |
46.2 |
31.2 |
|
Goodwill, Net |
151.9 |
154.4 |
166.0 |
156.9 |
147.5 |
|
Other Non-current Assets |
0.2 |
1.7 |
1.7 |
1.2 |
1.1 |
|
Shareholding |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Deferred Tax |
61.1 |
56.7 |
47.8 |
42.5 |
40.8 |
|
LT Receivables |
3.7 |
5.0 |
1.3 |
3.7 |
2.3 |
|
Investments/Equity Method |
0.0 |
0.1 |
0.2 |
0.2 |
0.0 |
|
Total Assets |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
Short Term Debt |
7.9 |
4.6 |
2.6 |
3.0 |
0.9 |
|
Cur.Port.LT Debt |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
Trade Payables |
39.1 |
39.2 |
33.7 |
38.5 |
35.7 |
|
Pybl./Affiliates |
17.7 |
14.9 |
13.2 |
13.0 |
16.9 |
|
Treasury Payables |
8.0 |
14.0 |
10.4 |
10.7 |
13.4 |
|
Inc. Tax Payable |
8.2 |
16.9 |
11.9 |
5.2 |
6.6 |
|
Cur.Port. Lease |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Accrued Expenses |
63.6 |
64.1 |
55.5 |
56.4 |
48.0 |
|
Reserves |
47.0 |
49.6 |
44.8 |
39.5 |
49.1 |
|
Deferred Income/Advances |
6.3 |
5.6 |
19.9 |
- |
- |
|
Social Security, Other Taxes |
27.7 |
23.7 |
8.5 |
- |
- |
|
Other Liabs. |
3.0 |
3.0 |
3.9 |
32.4 |
30.4 |
|
Total Current Liabilities |
231.3 |
238.0 |
219.9 |
201.4 |
216.9 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.4 |
13.6 |
26.4 |
18.7 |
|
Capital Lease |
20.7 |
22.8 |
24.7 |
26.1 |
27.9 |
|
Total Long Term Debt |
32.3 |
35.2 |
38.3 |
52.4 |
46.6 |
|
|
|
|
|
|
|
|
Deferred Tax |
5.8 |
8.9 |
14.2 |
16.0 |
16.0 |
|
Other Liabs. |
8.5 |
8.9 |
8.8 |
5.7 |
4.6 |
|
Pension |
17.8 |
19.2 |
16.6 |
16.8 |
16.0 |
|
Other Provisions |
17.4 |
20.5 |
15.8 |
9.7 |
5.7 |
|
Minority Int. |
47.0 |
36.4 |
27.7 |
17.9 |
13.7 |
|
Total Liabilities |
360.2 |
367.1 |
341.3 |
320.0 |
319.6 |
|
|
|
|
|
|
|
|
Share Capital |
109.1 |
111.0 |
118.9 |
114.2 |
115.6 |
|
Add. Paid-In Cap |
421.1 |
428.5 |
458.8 |
440.9 |
446.4 |
|
Retained Earning |
286.9 |
261.6 |
221.3 |
162.2 |
137.1 |
|
Other Comp. Inc. |
-13.4 |
-19.8 |
-37.6 |
-31.8 |
-28.4 |
|
Total Equity |
803.7 |
781.3 |
761.3 |
685.5 |
670.7 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders' Equity |
1,163.9 |
1,148.4 |
1,102.7 |
1,005.5 |
990.3 |
|
|
|
|
|
|
|
|
S/O-Bearer Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Accumulated Intangible Amortisation |
75.0 |
62.0 |
48.2 |
35.1 |
27.3 |
|
Advance Payments |
6.3 |
5.6 |
5.3 |
4.0 |
- |
|
Full-Time Employees |
2,366 |
2,189 |
2,147 |
2,152 |
1,929 |
|
LTD < 1 Year |
0.5 |
0.4 |
13.6 |
1.3 |
14.4 |
|
LTD < 2 Years |
8.5 |
0.4 |
0.4 |
13.3 |
0.4 |
|
LTD < 3 Years |
0.5 |
8.5 |
0.4 |
0.4 |
13.4 |
|
LTD < 4 Years |
0.6 |
0.5 |
9.1 |
0.4 |
0.4 |
|
LTD < 5 Years |
0.6 |
0.5 |
0.5 |
8.7 |
0.4 |
|
LTD < 6 Years |
0.6 |
0.5 |
0.5 |
0.5 |
0.5 |
|
LTD > 5 Years |
0.9 |
1.9 |
2.6 |
3.1 |
3.6 |
|
Total Long Term Debt, Supplemental |
12.2 |
12.8 |
27.2 |
27.6 |
33.1 |
|
Capital Lease within 1 Year |
2.2 |
2.1 |
1.9 |
1.5 |
1.4 |
|
Capital Lease from 1-5 Years |
10.8 |
9.6 |
8.6 |
7.9 |
7.2 |
|
Capital Lease over 5 Years |
9.9 |
13.1 |
16.1 |
18.1 |
20.7 |
|
Total Capital Leases |
22.8 |
24.8 |
26.6 |
27.5 |
29.4 |
|
Operating Lease within 1 Year |
10.5 |
7.3 |
6.7 |
6.6 |
4.4 |
|
Operating Lease within 2 Years |
- |
- |
8.3 |
7.8 |
4.1 |
|
Operating Lease from 1-5 Years |
13.9 |
10.9 |
8.3 |
7.8 |
4.1 |
|
Remaining |
7.5 |
0.9 |
2.0 |
2.6 |
0.6 |
|
Total Operating Leases |
31.9 |
19.1 |
25.2 |
24.8 |
13.1 |
|
Present Value of Defined Benefit Oblig. |
98.1 |
96.2 |
71.8 |
58.4 |
63.5 |
|
Fair Value of Plan Assets |
64.2 |
58.3 |
57.7 |
51.1 |
56.8 |
|
Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Total Funded Status |
-33.9 |
-37.9 |
-14.0 |
-7.3 |
-6.6 |
|
Discount Factor - Germany |
5.20% |
4.70% |
6.00% |
6.40% |
5.25% |
|
Long-Term Salary Increase - Germany |
3.00% |
3.00% |
3.00% |
3.00% |
3.00% |
|
Future Pension Increase - Germany |
2.00% |
2.00% |
2.00% |
2.00% |
1.75% |
|
Anticipated Return on Plan Assets - Germ |
4.50% |
4.50% |
5.00% |
5.00% |
5.00% |
|
Discount Factor - USA |
4.55% |
5.50% |
- |
- |
- |
|
Long-Term Salary Increase - USA |
4.00% |
3.50% |
- |
- |
- |
|
Future Pension Increase - USA |
4.00% |
4.00% |
- |
- |
- |
|
Anticipated Return on Plan Assets - USA |
7.50% |
7.50% |
- |
- |
- |
|
Discount Factor - Japan |
1.00% |
1.00% |
- |
- |
- |
|
Long-Term Salary Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Future Pension Increase - Japan |
2.54% |
2.54% |
- |
- |
- |
|
Discount Factor - Other |
- |
- |
1.50% |
1.50% |
1.70% |
|
Long-Term Salary Increase - Other |
- |
- |
2.54% |
3.50% |
3.50% |
|
Future Pension Increase - Other |
- |
- |
2.54% |
3.80% |
3.80% |
|
Anticipated Return on Plan Assets -Other |
- |
- |
7.50% |
8.00% |
8.00% |
|
Net Defined Benefit Plan Assets |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Net Assets Recognized on Balance Sheet |
-17.8 |
-19.2 |
0.0 |
0.0 |
-16.0 |
|
Assets which Cannot Be Offset |
- |
- |
- |
0.00% |
0.04% |
|
Equity Instruments |
23.54% |
20.69% |
27.39% |
18.38% |
33.82% |
|
Debt Instruments |
53.66% |
56.50% |
55.14% |
54.09% |
39.97% |
|
Cash |
8.51% |
7.80% |
13.70% |
23.25% |
14.70% |
|
Other |
14.29% |
15.01% |
3.77% |
4.27% |
11.46% |
Interim Balance Sheet
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745323 |
0.689727 |
0.704672 |
0.745406 |
0.732493 |
|
|
|
|
|
|
|
|
Inventories |
179.3 |
201.1 |
187.8 |
169.7 |
162.8 |
|
Trade Rcvbls. |
180.8 |
156.5 |
155.5 |
131.0 |
133.9 |
|
Rcvbl./Affiliate |
54.5 |
63.6 |
61.7 |
54.3 |
43.8 |
|
Treasury Receivables |
19.4 |
22.9 |
17.1 |
21.1 |
33.8 |
|
Cash |
261.1 |
239.5 |
303.0 |
427.0 |
428.0 |
|
Tax Receivables |
2.3 |
6.4 |
7.6 |
10.5 |
11.9 |
|
Other Assets |
149.9 |
166.6 |
163.6 |
2.4 |
14.9 |
|
Other Non-Financial Assets |
12.5 |
15.2 |
13.5 |
14.4 |
- |
|
Securities |
0.0 |
0.0 |
0.0 |
0.2 |
0.1 |
|
Total Current Assets |
859.8 |
871.7 |
909.9 |
830.5 |
829.2 |
|
|
|
|
|
|
|
|
Goodwill, Net |
151.9 |
162.9 |
159.7 |
152.0 |
154.4 |
|
Other Intangible, Net |
32.4 |
37.3 |
39.9 |
41.6 |
46.3 |
|
Property/Plant, Net |
54.3 |
53.6 |
53.6 |
51.9 |
54.5 |
|
Investments |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
|
Deferred Tax |
61.1 |
67.6 |
67.3 |
64.1 |
56.7 |
|
LT Receivables |
3.7 |
4.7 |
4.4 |
4.4 |
5.0 |
|
Other Non-current assets |
0.2 |
2.1 |
1.8 |
1.7 |
1.7 |
|
Investments/Equity Method |
0.0 |
0.0 |
0.0 |
0.0 |
0.1 |
|
Total Assets |
1,163.9 |
1,200.3 |
1,237.1 |
1,146.7 |
1,148.4 |
|
|
|
|
|
|
|
|
Short Term Debt |
7.9 |
3.8 |
4.3 |
5.8 |
4.6 |
|
Cur.Port.LT Debt |
0.5 |
0.4 |
0.4 |
0.5 |
0.4 |
|
Cur.Port. Lease |
2.2 |
2.2 |
2.1 |
2.1 |
2.1 |
|
Trade Payables |
39.1 |
31.2 |
38.5 |
28.9 |
39.2 |
|
Pybl./Affiliates |
17.7 |
16.0 |
20.6 |
11.1 |
14.9 |
|
Treasury Payables |
8.0 |
14.6 |
15.9 |
14.4 |
14.0 |
|
Inc. Tax Payable |
8.2 |
4.7 |
17.3 |
13.3 |
16.9 |
|
Accrued Expenses |
63.6 |
73.9 |
69.7 |
59.6 |
64.1 |
|
Reserves |
47.0 |
58.2 |
50.4 |
50.0 |
49.6 |
|
Other Liabs. |
37.0 |
36.8 |
37.4 |
43.1 |
32.3 |
|
Total Current Liabilities |
231.3 |
242.0 |
256.6 |
228.8 |
238.0 |
|
|
|
|
|
|
|
|
Long Term Debt |
11.7 |
12.9 |
12.7 |
12.0 |
12.4 |
|
Capital Lease |
20.7 |
21.4 |
22.1 |
22.3 |
22.8 |
|
Total Long Term Debt |
32.3 |
34.3 |
34.8 |
34.3 |
35.2 |
|
|
|
|
|
|
|
|
Deferred Tax |
5.8 |
8.2 |
8.8 |
8.9 |
8.9 |
|
Other Liabs. |
8.5 |
8.6 |
8.9 |
9.2 |
8.9 |
|
Pension |
17.8 |
19.8 |
17.8 |
16.1 |
19.2 |
|
Other Reserves |
17.4 |
20.7 |
19.7 |
20.0 |
20.5 |
|
Minority Interest |
47.0 |
43.3 |
40.9 |
38.5 |
36.4 |
|
Total Liabilities |
360.2 |
376.9 |
387.6 |
355.8 |
367.1 |
|
|
|
|
|
|
|
|
Share Capital |
109.1 |
117.9 |
115.4 |
109.1 |
111.0 |
|
Add. Paid-In Cap |
421.1 |
455.1 |
445.4 |
421.1 |
428.5 |
|
Retained Earning |
286.9 |
283.9 |
318.4 |
275.6 |
261.6 |
|
Other Comp. Inc. |
-13.4 |
-33.4 |
-29.7 |
-14.8 |
-19.8 |
|
Total Equity |
803.7 |
823.4 |
849.5 |
790.9 |
781.3 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders' Equity |
1,163.9 |
1,200.3 |
1,237.1 |
1,146.7 |
1,148.4 |
|
|
|
|
|
|
|
|
S/O-Bearer Shares |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
Total Common Shares Outstanding |
81.3 |
81.3 |
81.3 |
81.3 |
81.3 |
|
T/S-Bearer Shares |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Full-Time Employees |
2,366 |
2,287 |
2,245 |
2,209 |
2,189 |
|
Current maturities |
- |
- |
6.9 |
2.6 |
2.5 |
|
Total Long Term Debt, Supplemental |
- |
- |
6.9 |
2.6 |
2.5 |
|
Optg leases-year 1 |
- |
- |
- |
- |
7.3 |
|
Optg leases-year 2 |
- |
- |
- |
- |
10.9 |
|
Optg leases-year 6+ |
- |
- |
- |
- |
0.9 |
|
Total Operating Leases |
- |
- |
- |
- |
19.1 |
Annual Cash Flows
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Sep-2010 |
30-Sep-2009 |
30-Sep-2008 |
30-Sep-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.740255 |
0.73971 |
0.666382 |
0.752073 |
|
Auditor |
KPMG AG |
KPMG LLP |
KPMG LLP |
KPMG LLP |
KPMG LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Income Before Minority Interest |
100.7 |
80.6 |
74.5 |
84.4 |
66.0 |
|
Depreciation |
26.4 |
28.3 |
22.1 |
19.1 |
15.7 |
|
Income Tax Expenses |
39.9 |
31.5 |
31.8 |
29.2 |
35.2 |
|
Interest Income/Expenses |
3.7 |
4.9 |
1.0 |
-6.1 |
-4.4 |
|
Appreciation and Write-ups |
- |
- |
- |
0.0 |
0.0 |
|
Amortisation of Financial Assets |
- |
- |
- |
0.0 |
0.0 |
|
Sale of Fixed Assets |
1.1 |
-0.3 |
-0.1 |
-0.4 |
0.9 |
|
Sale of Pharma Business |
0.0 |
-1.6 |
- |
- |
- |
|
Interest and Dividends Received |
3.3 |
2.7 |
6.9 |
11.1 |
12.5 |
|
Interest Paid |
-4.4 |
-3.3 |
-4.0 |
-5.6 |
-5.2 |
|
Income Tax Refund |
25.1 |
4.4 |
5.1 |
5.2 |
4.1 |
|
Income Tax Paid |
-77.6 |
-47.2 |
-35.3 |
-47.2 |
-36.8 |
|
Accounts Receivable |
-57.1 |
-17.6 |
-2.7 |
5.4 |
-10.0 |
|
Inventories |
-21.2 |
-22.6 |
27.9 |
-19.9 |
-21.9 |
|
Other Assets |
4.3 |
1.5 |
-6.9 |
4.3 |
-2.7 |
|
Accounts Payable |
1.1 |
7.2 |
-7.6 |
-8.0 |
4.1 |
|
Provisions and Financial Liabilities |
2.6 |
18.9 |
3.0 |
7.6 |
2.8 |
|
Other Liabilities |
4.6 |
0.7 |
2.3 |
3.2 |
7.3 |
|
Consolidation |
- |
- |
- |
0.0 |
-0.1 |
|
Pension Receivables |
- |
- |
- |
0.0 |
7.0 |
|
Results from Investments/Equity Method |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Cash from Operating Activities |
52.3 |
88.1 |
118.1 |
82.3 |
74.6 |
|
|
|
|
|
|
|
|
Restricted Cash |
- |
- |
- |
0.0 |
6.2 |
|
Purchase Fixed Asset |
-8.0 |
-6.2 |
-14.0 |
-11.4 |
-6.8 |
|
Sale of Fixed Assets |
0.8 |
1.0 |
0.6 |
1.2 |
0.2 |
|
Acquisition of Carl Zeiss SA Spain |
- |
- |
- |
0.0 |
-5.0 |
|
Acquisition of Consolidated Companies |
- |
0.0 |
-15.7 |
-32.1 |
-6.8 |
|
Proceeds/Loans |
- |
- |
- |
0.0 |
0.0 |
|
Securities |
-153.3 |
0.0 |
0.0 |
7.4 |
-6.6 |
|
Sale Subsidiary |
0.0 |
5.4 |
- |
0.0 |
-0.2 |
|
Purchase Intangibles |
-1.0 |
-9.5 |
-8.2 |
-8.2 |
-2.1 |
|
Purchase of Investment |
-6.0 |
-2.1 |
-4.1 |
-3.1 |
-4.2 |
|
Acquisition of Surgical Business |
- |
- |
- |
0.0 |
0.9 |
|
Repayment of Loans to A Former Sharehol. |
- |
- |
0.0 |
9.2 |
0.0 |
|
Repayment of Loans |
- |
- |
0.0 |
0.0 |
0.0 |
|
Investment in Interest |
- |
- |
0.0 |
-0.2 |
0.0 |
|
Cash from Investing Activities |
-167.5 |
-11.4 |
-41.4 |
-37.2 |
-24.3 |
|
|
|
|
|
|
|
|
ST Debt Repaid |
0.1 |
0.0 |
-0.2 |
-2.3 |
0.0 |
|
ST Debt, Net |
- |
- |
- |
0.0 |
-2.4 |
|
LT Debt Repaid |
-0.4 |
-0.6 |
-0.8 |
-2.6 |
-0.5 |
|
Repay. Capital Lease |
-1.9 |
-1.7 |
-1.4 |
-1.5 |
-1.2 |
|
Loans from Related Issued |
- |
- |
0.0 |
-13.2 |
0.0 |
|
Loans from Related Repayed |
0.0 |
-11.7 |
- |
- |
- |
|
Treasury Liabs., Net |
-6.0 |
4.2 |
-0.7 |
-2.7 |
-20.5 |
|
Rcvbls/Treasury, Net |
15.0 |
103.9 |
-47.8 |
0.2 |
-4.8 |
|
Capital Increase |
- |
- |
- |
0.0 |
232.1 |
|
Cost of Capital Increase |
- |
- |
- |
0.0 |
-8.8 |
|
Acquisition of Minority Interest |
0.0 |
-0.1 |
- |
- |
- |
|
Dividends Paid to Minority |
- |
- |
- |
0.0 |
0.0 |
|
Payments to CZ Medical AG |
-62.3 |
-19.8 |
-19.8 |
-52.5 |
-15.1 |
|
Treasury Stock |
- |
- |
- |
0.0 |
0.0 |
|
Cash from Financing Activities |
-55.5 |
74.3 |
-70.6 |
-74.6 |
178.9 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
2.4 |
0.0 |
-4.2 |
-1.4 |
|
Net Change in Cash |
-165.6 |
153.4 |
6.1 |
-33.7 |
227.7 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
270.2 |
264.3 |
327.0 |
62.0 |
|
Net Cash - Ending Balance |
271.2 |
423.5 |
270.4 |
293.3 |
289.8 |
|
Cash Interest Paid |
4.4 |
3.3 |
4.0 |
5.6 |
5.2 |
|
Cash Taxes Paid |
52.6 |
42.8 |
30.1 |
42.1 |
32.7 |
Interim Cash Flows
As Reported
Financials in: USD (mil)
Except for share items (millions) and per share items (actual units)
|
|
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
30-Sep-2010 |
|
Period Length |
12 Months |
9 Months |
6 Months |
3 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
EUR |
EUR |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.717768 |
0.72104 |
0.733879 |
0.736368 |
0.740255 |
|
|
|
|
|
|
|
|
Net Income Before Minority Interest |
100.7 |
73.1 |
48.9 |
19.8 |
80.6 |
|
Depreciation |
26.4 |
19.6 |
13.5 |
7.0 |
28.3 |
|
Income Tax Expenses |
39.9 |
34.9 |
23.2 |
10.7 |
31.5 |
|
Interest Income/Expenses |
3.7 |
1.8 |
1.2 |
0.6 |
4.9 |
|
Sale of Fixed Assets |
1.1 |
0.4 |
0.1 |
0.4 |
-0.3 |
|
Sale of Pharma Business |
0.0 |
- |
- |
- |
-1.6 |
|
Interest and Dividends Received |
3.3 |
2.8 |
2.4 |
1.1 |
2.7 |
|
Interest Paid |
-4.4 |
-3.3 |
-2.3 |
-0.8 |
-3.3 |
|
Income Tax Refund |
25.1 |
7.8 |
7.4 |
3.5 |
4.4 |
|
Income Tax Paid |
-77.6 |
-58.3 |
-31.8 |
-21.6 |
-47.2 |
|
Accounts Receivable |
-57.1 |
-33.6 |
-34.2 |
-7.8 |
-17.6 |
|
Inventories |
-21.2 |
-33.3 |
-22.6 |
-7.5 |
-22.6 |
|
Other Assets |
4.3 |
-5.9 |
-5.7 |
-2.2 |
1.5 |
|
Accounts Payable |
1.1 |
-7.8 |
4.3 |
-14.4 |
7.2 |
|
Provisions and Financial Liabilities |
2.6 |
13.4 |
0.0 |
-3.1 |
18.9 |
|
Liabilities |
4.6 |
2.7 |
4.4 |
11.3 |
0.7 |
|
Results from Investments/Equity Method |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Cash from Operating Activities |
52.3 |
14.2 |
8.9 |
-3.0 |
88.1 |
|
|
|
|
|
|
|
|
Purchase Fixed Asset |
-8.0 |
-4.4 |
-3.4 |
-1.2 |
-6.2 |
|
Purchase Intangibles |
-1.0 |
-0.6 |
-0.4 |
0.0 |
-9.5 |
|
Purchase of Investment |
-6.0 |
-5.5 |
-5.3 |
-5.3 |
-2.1 |
|
Sale of Fixed Assets |
0.8 |
0.4 |
0.4 |
0.2 |
1.0 |
|
Investment in Deposits |
-153.3 |
-152.6 |
-149.9 |
- |
0.0 |
|
Acquisition of Companies |
- |
0.1 |
0.1 |
- |
- |
|
Acquisition of Consolidated Companies |
- |
0.0 |
0.0 |
- |
0.0 |
|
Sale of Business |
0.0 |
0.0 |
0.0 |
0.1 |
5.4 |
|
Cash from Investing Activities |
-167.5 |
-162.7 |
-158.5 |
-6.3 |
-11.4 |
|
|
|
|
|
|
|
|
Repayment S/T Debt |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Proceeds/LT Debt |
-0.4 |
-0.3 |
-0.2 |
-0.1 |
-0.6 |
|
Repayment of Loans - Related |
0.0 |
0.0 |
0.0 |
0.0 |
-11.7 |
|
Treasury Liabs., Net |
-6.0 |
-0.3 |
1.3 |
0.7 |
4.2 |
|
Rcvbls/Treasury, Net |
15.0 |
12.2 |
16.9 |
12.5 |
103.9 |
|
Repay. Capital Lease |
-1.9 |
-1.5 |
-0.6 |
-0.4 |
-1.7 |
|
Acquisition of Minority Interest |
0.0 |
- |
- |
- |
-0.1 |
|
Payments to CZ Medical AG |
-62.3 |
-62.0 |
0.0 |
- |
-19.8 |
|
Cash from Financing Activities |
-55.5 |
-51.9 |
17.3 |
12.7 |
74.3 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
5.1 |
-5.3 |
-4.0 |
3.0 |
2.4 |
|
Net Change in Cash |
-165.6 |
-205.7 |
-136.2 |
6.5 |
153.4 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
436.8 |
434.8 |
427.2 |
425.8 |
270.2 |
|
Net Cash - Ending Balance |
271.2 |
229.1 |
291.0 |
432.2 |
423.5 |
|
Cash Interest Paid |
4.4 |
3.3 |
2.3 |
0.8 |
3.3 |
|
Cash Taxes Paid |
52.6 |
50.5 |
24.4 |
18.2 |
42.8 |
Geographic
Segments
Financials in: As Reported (mil)
|
Annual |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic Segments
Financials in: As Reported (mil)
|
Interim |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business
Segments
Financials in: As Reported (mil)
|
Annual |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gross Profit USD (mil) 30-Sep-11 30-Sep-10 30-Sep-09 Ophtamalogic
Systems 239.9 41.5 % 210.5 43.4
% 185.5 42.6 % Surgery
Ophtamology 71.5 12.4 % 67.0 13.8
% 60.1 13.8 % Micro/Neuro
Surgery 266.5 46.1 % 207.1 42.7
% 190.1 43.6 % Segment Total 578.0 100 % 484.6 100
% 435.7 100 % Consolidated
Total 578.0 100 % 484.6 100
% 435.7 100 % Exchange Rate:
EUR to USD 0.717768 0.740255 0.739710 Gross Margin (%) 30-Sep-11 30-Sep-10 30-Sep-09 Ophtamalogic
Systems 49.8 - 48.3 - 44.2 - Surgery
Ophtamology 56.6 - 57.9 - 56.2 - Micro/Neuro
Surgery 59.4 - 57.1 - 56.2 - Segment Total 54.7 - 53.0 - 50.4 - Consolidated
Total 54.7 - 53.0 - 50.4 -
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business
Segments
Financials in: As Reported (mil)
|
Interim |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.50.91 |
|
UK Pound |
1 |
Rs.81.21 |
|
Euro |
1 |
Rs.67.85 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.